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Pneumocystis is an opportunistic fungal pathogen that presents as a pulmonary 
pneumonia. Originally characterized as an AIDs-defining illness, Pneumocystis has now 
reemerged in non-HIV immunocompromised patients. It has been shown that Pneumocystis 
prophylaxis of can reduce the incidence of infection, severity of disease, and mortality rate in 
immunocompromised patients. However, prophylaxis is relatively toxic, and only prescribed to 
defined at risk populations. Anti-CD20 was originally a therapy for B-cell non-Hodgkin 
lymphomas, but now it’s also used to treat hematological malignancies, autoimmune diseases, 
and post-transplant lymphoproliferative disease. Studies have shown that up to 30% of patients 
receiving anti-CD20 antibodies developed Pneumocystis pneumonia, however, many of these 
patients were also on concomitant immunosuppressive drugs which complicates any analyses of 
clinical studies. Thus, we generated a murine model of anti-CD20 therapy, and demonstrated 
treatment does induce susceptibility to Pneumocystis infection. This correlated to an overall 
decrease in immune response, but more specifically a loss in CD4+ T-cell mediated protection.  
The predominant factor required for immunity against Pneumocystis infection is the 
presence of CD4+ T-cells. This has been validated several times over by clinical data and 
experimental animal models. Early on, studies have examined the role of T helper 1 (Th1), T 
helper 2 (Th2), and T helper 17 (Th17) cells. To briefly summarize these studies, Th1, Th2, and 
Th17 cells can all be detected in the lung during infection, however, removal of their classically 
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defined effector molecules only delayed clearance or had no effect. We examined the importance 
of each subset of T helper cells by deleting the Stat transcription factors that mediated 
differentiation. We found that specifically Stat3 was required, however, it was independent of 
IL-17 and IL-23 signals. We also identified IL-21 as a key cytokine required to mediate 
clearance. Using a variety of approaches, we determined that GM-CSF and IL-22 play important 
roles during Pneumocystis infection. GM-CSF+ CD4+ T-cells are critical for T-cell mediated 
clearance, however, it alone is not sufficient. While IL-22, although not required, was sufficient 
to reduce burden in IL-21 receptor knockout mice. These data suggest a model of clearance, 
requiring non-classical T helper cell function.   
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1.0  CHAPTER ONE: INTRODUCTION 
1.1 THE PATHOGEN 
1.1.1 History and Taxonomy of Pneumocystis 
Pneumocystis is a fungal genus that was first discovered in 1909 by Carlos Chagas (1979-1934). 
Chagas was investigating trypanosomiasis in the Minas Gerais state of Brazil, and observed the 
cyst form of Pneumocystis in Cavia porcellus (guinea pigs) inoculated with blood from two 
children infected with Trypanosoma [1, 2]. He misidentified the cysts as a new genus of 
trypanosomes, calling them Schizotrypanum. In 1910, Antonio Carini (1872-1950), at Instituto 
Pasteur de São Paulo, also identified the same cystic organisms in the lungs of Rattus norvegicus 
(rats) during an experimental model of Trypanosoma lewisi infection, but also mischaracterized 
these cysts as a new genus of trypanosome [3]. Shortly after, Delanoë and Delanoë, fellows 
under Alphonse Laveran at Instituto Pasteur de São Paulo, received samples from Chagas and 
compared them to similar organisms they found in rats that were negative for Trypanosoma. 
These organisms did not acquire dissemination to the blood, and displayed a strict tropism to the 
lung, very uncharacteristic of trypanosomes. Thus, Delanoë and Delanoë reported that the 
organisms identified by both Chagas and Carini are unique from trypanosomes, and named the 
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genus Pneumocystis carinii, Pneumo- for the lung, -cytis for its circular morphology, and carinii 
after Antonio Carini [4, 5].  
The taxonomy of Pneumocystis had been under debate for many years due to its 
morphological features and life cycle. Its small cyst and large trophozoite lifeforms initially lead 
many scientists to conclude that Pneumocystis is a coccidian Protozoa [6, 7], however, there 
were still those who suggested that the organism more accurately resembled Fungi [8, 9].  In 
1988, Jeffrey Edman, with the use of small subunit ribosomal RNA analysis, was able to settle 
this debate by comparing the structural distances (average number of base changes per position) 
of the rRNA among several fungal, protozoan, and mammalian organisms. He concluded that 
Pneumocystis has strong structural similarity with Fungi, especially Sacchromyces cerevisiae, 
and a large structural distance from Protozoa [10]. Other studies have also shown that the 
thymidylate synthase and dihydrofolate reductase, beta tubulin, and mitochondrial DNA 
sequences of Pneumocystis have greater homology with Fungi than Protozoa. More recently, the 
sequencing of the Pneumocystis genome has validated it’s strong homology with other Fungi 
[11]. Thus, Pneumocystis has been listed under the Ascomycota phylum (subphylum 
Taphrinomycotina), closest known relative being Schizosacchromyces pombe, and given a 
unique class, order, and family [12]. Eukaryote Fungi Ascomycota Pneumocystidomycetes 
Pneumocystidales Pneumocystidaceae Pneumocystis carinii [13]. 
1.1.2 Pneumocystis Host Specificity and Nomenclature 
Since its initial discovery in rats and guinea pigs, Pneumocystis has been identified in nearly all 
mammalian species. The earliest known documentation of pneumocystosis was during World 
War II at an orphanage in Poland, where two malnourished infants presented with a diffuse 
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interstitial pneumonia.  The investigation was led by two Dutch physicians, van der Meer and 
Brug who identified Pneumocystis as the causative agent of the infection in the infants [5]. 
However, it wasn’t until 1952 that a Czech pathologist by the name, Otto Jirovec received credit 
for describing the first human case of Pneumocystis pneumonia. Initially, it was believed that 
humans infected with Pneumocystis acquired a zoonotic infection [14]. Experimentally however, 
although it was shown that Pneumocystis could be transmitted via an airborne route between 
animals of the same species, there were no successful attempts of interspecies infection. It was 
an unprecedented discovery, within the kingdom Fungi, for Pneumocystis to have such stringent 
host specificity. For example, Pneumocystis from an infected rat cannot successfully infect a 
mouse, and vice versa [15]. Historically, this required Pneumocystis to be labeled as distinct 
forms i.e. forma specialis (f.sp.). For example, the form of Pneumocystis that infects mice was 
referred to as Pneumocystis carinii f.sp. murina, while Pneumocystis carinii f.sp. hominis was 
reference to the form that infected humans [16]. 
The exact reason for this host and tissue tropism is still not known, however, 
Pneumocystis spp. have genetic and antigenic variations between the different forms. This 
discovery triggered a nomenclature change in the research community [17], so each form of 
Pneumocystis is now referred to as a distinct species. For example, Pneumocystis carinii f.sp. 
murina is now simply Pneumocystis murina.  Since Antonio Carini discovered the organism in 
rats; now only the rat form is named Pneumocystis carinii, and the human form is named after 
the pathologist Jirovec, Pneumocystis jirovecii [16, 18].  
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1.1.3 Pneumocystis Morphology and Life-Cycle 
Pneumocystis is a dimorphic organism with cystic and trophic lifeforms (Figure 1). The life-
cycle and basic biology of Pneumocystis is unique but very much understudied. The biggest 
limitation of Pneumocystis research is the inability for the organism to grow in vitro, so most 
studies of Pneumocystis morphology and life-cycle were done in a rabbit model of infection with 
Pneumocystis oryctolagi [19]. The majority of data generated on the specific structural features 
of Pneumocystis was generated in the 90’s by transmission electron microscopy, ultrastructural 
cytochemistry, and computational 3D reconstructions [20-22].  
 
Figure 1. Pneumocystis morphology 
Transmission electron microscopy of murine alveolar epithelial cells during Pneumocystis infection. The trophic 
form of Pneumocystis (yellow arrow) is amoeboid and binds directly to the surface of alveolar epithelial cells (white 
arrows) and each other. The cystic form of Pneumocystis (red arrows) is round, with a thick, β-1,3-glucan rich cell 
wall, and up to 8 ascospores per cyst (green arrows).   
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The accepted life-cycle of Pneumocystis begins with the transmissible and infectious 
form of the pathogen, the ascospore filled cyst. The ascospore has a visible outer membrane with 
a single layered electron-dense cell wall [23]. These grow/differentiate into trophozoites (trophs) 
that start off small (1-2 μm) and ellipsoid, but become larger (4-8 μm) and have irregular shapes 
(amoeboid). This irregularity is due to the numerous filopodia that sometimes are described as 
tree-like.  The trophic forms attach specifically to alveolar type-I (AT1) epithelial cells and begin 
their transition through three sporocytic stages (early, intermediate, and late) finally forming a 
mature cyst or ascus (Figure 2A). Early sporocytes are very similar to the trophic form 
(mononuclear, single-layered cell wall), except they have a rounded morphology. The 
intermediate sporocyte have an increase in cell wall thickness, primarily from β-1,3-glucan 
synthesis of the middle layer of the cell wall, and undergo multiple nuclear replications. The late 
sporocyte is denoted by the visual appearance of up to 8 nuclei; the invagination of the cyst 
membrane establishes the ascospores and completes the cystic stages [23, 24]. The surfaces of 
mature cysts have highly polymorphic mannose-rich antigens, known as major surface 
glycoproteins (MSG) [5, 25]. The MSGs are heterogeneous among the different species of 
Pneumocystis, however, intracellular proteins, such as kinases, are more closely conserved. It is 
speculated that the heterogeneity of the MSGs of Pneumocystis may play a role in their strict 
host specificity (Eddens et al. unpublished). Finally, the mature cysts release the ascospores 
through a small pore. 
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Figure 2. Pneumocystis reproduction 
A. The asexual method of Pneumocystis reproduction begins with the ascospore attaching to the alveolar epithelium 
and growing into a trophozoite. The trophozoite then matures into a mature cyst through 3 sporocytic stages (early, 
intermediate, and late). The mature cyst releases up to 8 ascospores through a tiny pore in its membrane. B. Two 
ascospores or trophs are suspected to be able to fuse with each other to initiate a sexual method of reproduction. C. 
Trophs are also suspected to be able to replicate without progression through sporocytic stages. Servier Medical Art 
was used to generate this figure.  
It is believed that Pneumocystis is also capable of sexual reproduction (Figure 2B), a trait 
more commonly found in plant-pathogenic fungi  [26]. The Pneumocystis genome project 
revealed many genes homologous to other Ascomycota that are involved in mating, meiosis, and 
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mitosis regulation, such as α-mating factor pheromone receptors and mitogen-activated protein 
kinases [11, 27, 28]. Although the in vitro limitations have made it difficult to confirm this 
hypothesis, modern tools including library screening, yeast complementation, and computer 
modeling have provided strong supporting evidence. Presence of diploid trophozoites is 
considered strong supporting evidence for this hypothesis, however, it is also believed that the 
trophozoite may also be able to replicate by an asexual binary fission (Figure 2C). Furthermore, 
rodents treated with β-1,3-glucan synthase inhibitors (caspofungin) are effectively depleted of 
the cyst form, but are still burdened by the trophic form. This suggests that the trophozoite can 
replicate without transitioning through sporocytic stages. Interestingly, these animals also lose 
their capacity to transmit infection, further confirming that the ascus is the transmissible form 
[29]. There is still much to be learned about the Pneumocystis life-cycle, however, discovering a 
means to culture the organism will be crucial.  
1.2 THE HOST 
1.2.1 Pneumocystis Epidemiology 
Populations with the highest risk for Pneumocystis pneumonia can be divided into two 
categories: Human Immunodeficiency Virus (HIV) positive, and HIV negative populations. The 
following section discusses the significance of each.  
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1.2.1.1 HIV Associated Pneumocystis Pneumonia 
Pneumocystis was originally considered a rare infection found in only malnourished and 
congenitally immunocompromised patients. There was a small increase in incidence with the 
start of solid organ transplantations, with 5-25% of transplant patients developing Pneumocystis 
pneumonia. However, rates nearly diminished after the introduction of chemoprophylaxis. It 
wasn’t until 1981, when the Center for Disease Control revealed its first report of Pneumocystis 
pneumonia, among homosexual men and intravenous drug users in Los Angeles, that 
pneumocystosis shifted from a rare disease to a common pneumonia [30]. This marked the 
beginning of the HIV-AIDS epidemic, with Pneumocystis jirovecii pneumonia (PJP) becoming 
the AIDS-defining diagnosis in HIV infected patients. Patients with CD4+ cell counts less than 
200 cells per microliter had an incidence rate as high as 20% per year, with a 75% risk of all HIV 
positive patients to develop PJP in their lifetime [31, 32].  
In the developed world, PJP accounted for two thirds of AIDS-defining illnesses, thus in 
1989 began the implementation of anti-Pneumocystis prophylaxis to all patients with CD4+ cell 
counts less 200 cells per microliter. The frequency PJP in AIDS patients reduced from 53% to 
42% over the next three years, however, the total number of Pneumocystis cases remained 
unaffected due to the spread of HIV [30, 33]. Another major decrease occurred in late 1995 with 
start of combined Anti-Retroviral Therapy (cART), in which the yearly Pneumocystis infection 
rate had decrease by half. Unfortunately, this has had little to no effect on the mortality rate, 
which only shifter from 10.1% to 9.7% [34].  
Even with the advent of anti-Pneumocystis prophylaxis and cART, Pneumocystis 
jirovecii still remains the most diagnosed AIDS-defining opportunistic infection in the United 
States [35]. In the past, studies have shown that most cases were of patients unaware of their 
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HIV status and/or were not receiving treatment, however, up to 40% of HIV positive patients 
diagnosed with PJP were in fact receiving prophylaxis. These patients may have acquired a drug 
resistant strain of Pneumocystis or were too immunocompromised for the prophylaxis to be 
efficacious [36].  
In developing countries, where anti-Pneumocystis prophylaxis and cART availability are 
limited, HIV associated Pneumocystis pneumonia is still a major clinical complication. Studies 
have shown that over 30% of southern Africans presenting with diffuse pneumonia have tested 
positive for the presence of Pneumocystis in bronchoalveolar lavage fluid (BALF) [37, 38]. 
Many Southeast Asian countries have up to a 25% incidence of Pneumocystis infection in HIV-
positive populations, while South American countries, such as Chile and Venezuela, report 
incidences as high as 37%.  
1.2.1.2 Non-HIV Associated Pneumocystis Pneumonia 
At the turn of the century, Pneumocystis infection has reemerged in developed countries, 
primarily in HIV-negative populations. In Sweden, a 10-year study at Sahlgrenska University 
Hospital revealed that the numbers of Pneumocystis cases over the course of the study had not 
changed, and more surprisingly, 75% of the patients were HIV negative. Less than 20% of 
patients received prophylaxis prior to developing Pneumocystis suggesting that many at risk 
populations have not been identified [39].  Another study reported that, although the incidence of 
HIV-positive PJP had decreased, the total number of confirmed Pneumocystis cases had 
increased an average of 7% per year. The primary at risk populations were patients that had 
received a transplant, or had a hematologic malignancy [40]. A large number of conditions (and 
therapeutic agents) can be statistically correlated with Pneumocystis infection, briefly these 
include: hematological malignancies and solid tumors (alkylating agents), transplantation  
 10 
Table 1. Genes Associated with Pneumocystis Susceptibility 
Loss-of-function 
Gene Mutation 
Susceptibility to Pneumocystis 
Human Murine 
RAG1 + + 
RAG2 + + 
CD40-CD40L + + 
PRKDC + + 
IL-2Rγ + + 
CD4 + + 
HLA/MHC class II + + 
IΚBKΓ + N/I 
ICOS + N/I 
BTK + N/I 
STAT3 (polymorphism)* + + 
IL-21R* + + 
Human (+): Clinical diagnosis in patients with mutation.  
Murine (+): Validated using experimental models.  
N/I: Not yet investigated. *: To be described in Chapter 3. 
 
(antimetabolite chemotherapeutics and azathioprine), autoimmune disorders (corticosteroids and 
TNF inhibitors), hyper-IgM syndrome, B-cell lymphomas and leukemia’s (Rituximab and 
Alemtuzumab), and congenital immunodeficiency [41]. Some of these conditions and/or 
associated treatments affect non-CD4+ T-cell compartments, but these patients are remarkably 
susceptible to Pneumocystis infection. In addition, these cases typically have increased morbidity 
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and higher mortality rates than HIV-positive associated PJP cases [42, 43]. Many genetic 
mutations have been associated with Pneumocystis susceptibility, and interestingly, most of these 
targets have also been replicated experimentally using murine studies (Table 1).  
1.2.2 Clinical Features and Diagnosis 
HIV positive and non-HIV associated Pneumocystis pneumonia have very different clinical 
presentations. HIV positive patients’ symptoms typically present with a low-grade fever, 
progressive dyspnea (shortness of breath), and an unproductive cough. Immunocompromised 
HIV negative patients have substantially more acute symptoms such as severe dyspnea and high 
fevers. Urgent need for mechanical ventilation is not uncommon, and respiratory failure accounts 
for 40% of the mortality rate. Although the non-HIV populations typically have greater disease 
severity, the HIV-positive populations usually have higher fungal burden, as measured in BAL 
[44]. Disease severity closely correlates with neutrophil and inflammatory cell numbers [45].  
These symptoms, especially in immunocompromised patients, should be the primary 
indicator for physicians to request further evaluation for Pneumocystis infection. In many cases, 
radiological findings such as bilateral pulmonary infiltrates may be seen on chest X-ray (CXR). 
However, Pneumocystis infection may present less common patterns such as lobar infiltrates, 
pneumothorax, pneumatoceles, or pulmonary nodules, or may even present with normal 
radiographs. These cases are typically followed up by high-resolution chest CT, which generally 
reveal bilateral ground-glass opacities [44]. Although symptomology and radiographic evidence 
may strongly suggest an underlying Pneumocystis infection, microscopic visualization is still the 
gold standard for diagnosis.  Typically, organisms from bronchoalveolar lavage or induced 
sputum samples are stained with Gomori-methenamine silver (GMS) stain, however, other stains 
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such as Wright-Giemsa, Calcofluor white, and toluidine blue O can also be used to detect 
Pneumocystis organisms. Currently, fluorescently-labelled monoclonal antibodies appear to have 
the greatest sensitivity and specificity [46].  
Unfortunately, visual examination may generate false-negative results, primarily in non-
HIV patients who tend to have a lower infectious burden [47]. A few molecular methods have 
been adopted to help with the diagnosis of these patient populations. One of these was single 
round Polymerase Chain Reaction (PCR), which amplified the mitochondrial ribosomal RNA of 
Pneumocystis. To increase the sensitivity, nested-PCR (two round of PCR amplification) was 
incorporated on a variety of target genes, including rRNAs, major surface glycoproteins (MSG), 
dihydrofolate reductase (DHFR), and dihydropteroate synthase [48, 49]. However, these could 
not distinguish patients colonized with Pneumocystis versus patients with active Pneumocystis 
pneumonia [50].   
To help distinguish colonization from active infection, techniques such as quantitative 
real-time PCR (RT-PCR) have been incorporated.  This assay provides expedient, specific, 
highly sensitive, and most importantly quantifiable results that can be used to estimate fungal 
burden in patients. This has been demonstrated in several studies using a variety of genes 
including MSG, which has been shown to have a 100% specificity and 98.6% sensitivity in both 
HIV-positive and HIV-negative patients [51]. However, before RT-PCR can be fully 
implemented as a primary tool for diagnosing Pneumocystis, standardization of the assay to 
distinguish colonization and active human infection is still required. In the research community, 
using RT-PCR to quantify burden in infected animals has become common practice. The 
mitochondrial Large Subunit (LSU) ribosomal RNA is more broadly used to assess 
Pneumocystis burden. However, our lab had determined that primers and probes against the 
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mitochondrial Small Subunit (SSU) ribosomal RNA had less background genomic amplification 
(Figure 3). In addition, RNA sequencing of trophozoite enriched organism has allowed us to 
identify troph and cyst specific genes, arp1 and sp, respectively (unpublished). 
 
Figure 3. P. murina quantification mitochondrial LSU vs SSU rRNA 
Live Pneumocystis inoculum was either washed with 70% ethanol (right boxplot), heat killed at 95ºC for 15 minutes 
(center boxplot), or left untreated (left boxplot). Samples were reverse transcribed (labeled cDNA) or underwent no 
RT reactions (labeled RNA). Then amplified by Large Subunit (LSU) or Small Subunit (SSU) primer/probe 
combinations. The SSU primer/probe set had the least background in the no RT control samples.  
As described in 1.1.3, the Pneumocystis ascus cell wall is composed of β-1,3-glucans, and 
can be detected in serum during active infection. Diagnosing Pneumocystis infection with serum 
β-1,3-glucans levels above 100pg/mL had a sensitivity and specificity of 100% and 96.4%, 
respectively [52]. However, β-1,3-glucans are also present on other fungal species, thus as a 
marker, it is unable to discriminate Pneumocystis from other fungal pathogens. Another serum 
marker Pneumocystis pneumonia is KL-6, a surface glycoprotein. Although KL-6 is a more 
specific marker, studies have only confirmed elevated serum KL-6 levels in HIV-positive cases. 
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1.2.3 Treatment and Prophylaxis   
The recommended first-line therapy for mild to severe Pneumocystis pneumonia is trimethoprim-
sulfamethoxazole (TMP-SMX). The standard dose is given by separate administrations of 15-20 
mg/kg/day of TMP and 75-100mg/kg/day SMX orally, however, intravenous (IV) administration 
may be used for severe cases. SMX requires extensive hepatic metabolism followed by renal 
excretion, thus doses are typically adjusted for patients with liver and kidney failure. It is 
standard to measure drug levels at least once after administration to insure adequate dosing and 
to avoid toxicities. TMP-SMX have adverse side-effects such as rash, vomiting, diarrhea, and 
cytopenia, and is not recommended for patients with sulfa allergies [53-55]. Aerosolized 
pentamidine was an alternative option for treatment, however, it was associated with disease 
dissemination, and is currently a last resort medication.  Intravenous pentamidine has better 
success at controlling infection, however it also has more severe side effects such as hypotension 
and pancreatitis. More recently, combination drugs (e.g. primaquine and clindamycin) have been 
effective treatments, with higher tolerance than IV pentamidine [44]. Echinocandins inhibit β-
1,3-glucan synthesis, which affect the development of the ascus cell wall. Rodents treated with 
echinocandins have reduced asci, but are still burdened by the trophic form. Caspofungin, an 
echinocandin, has been shown to have a therapeutic effect when administered with a low-dose of 
TMP-SMX. This was particularly effective with renal transplant patients that cannot handle the 
typical dose of TMP-SMX [56]. Patients treated with echinocandins should be monitored for 
Pneumocystis burden by quantitative PCR, because the disruption of the cell wall may render 
false-negatives by visual GMS staining [29]. 
A typical regimen for treating Pneumocystis pneumonia lasts for approximately 3 weeks, 
however, if disease is still progressing past the first week of treatment, then drug-resistance 
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should be suspected. Drug resistance is associated with Pneumocystis gene mutations, such as 
dihydropteroate synthase gene (DPHS) [57, 58]. Prophylaxis administration depends on the 
particular condition inducing immunosuppression, thus should be individualized. HIV-positive 
patients maintain treatment for as long as their CD4 counts are below 200 cell per microliter. 
Similarly, HIV-negative patients categorized for at risk of Pneumocystis infection are treated for 
as long as the immunosuppressive agents are in effect. This becomes complicated for HIV-
negative patients who may remain immunosuppressed months after completion of a cytotoxic 
regimen such as cyclophosphamide. Thus patients should be monitored for at least 6 months post 
immunosuppression.   
1.2.4 Immune Reconstitution Inflammatory Syndrome 
Immune reconstitution inflammatory syndrome (IRIS) is a pathological immune response to an 
opportunistic infection that occurs during the recovery from an immunosuppressive condition or 
agent. This syndrome was originally characterized in HIV/AIDS patients that have a positive 
response to cART, followed by an inflammatory condition. Approximately 16% of HIV-positive 
patients on cART develop IRIS, and typically present with fever, dyspnea, and may develop 
respiratory failure. Combination antiretroviral therapy would deplete HIV, repopulate CD4+ T-
cells, and restore the host’s adaptive immunity.  Infections developed during immunosuppression 
become unmasked, and the immune system initiates an exaggerated immune response that can 
cause serious damage to the host. There is a second form of IRIS, referred to as paradoxical 
IRIS, which occurs despite the absence of a serious infection. In cases where patients may have 
had treatment for an acquired infection, however, residual antigens from the infection linger and 
trigger the exaggerated response [59-61].   
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Mycobacterium and Cryptococcus are the infections most commonly associated with 
IRIS, however, Pneumocystis accounts for up to 4% of cases.  It is important to note that an 
accurate measure of IRIS incidence is difficult due to the lack of a consensus of diagnostic 
criteria, and variability in the time of onset post cART, spanning from 2 months up to a year [59, 
62, 63]. The direct relationship between severity of immunosuppression (i.e. low CD4 counts, 
high viral load) and the risk for development of Pneumocystis-associated IRIS can be concluded. 
Interestingly, studies have also suggested that early treatment with cART also increases risk of 
IRIS, in contrast, delayed treatment with cART increases Pneumocystis related mortality [64, 
65].  
Treating the underlying infection with TMP-SMX is the primary approach to help 
manage the severity of IRIS. If possible, recognizing the immunosuppressive cause of infection 
and complementing the immune system is considered most efficient in treating IRIS. In HIV-
positive cases that may develop life-threatening IRIS due to large Pneumocystis burden, 
treatment of the inflammatory environment with glucocorticoids may become necessary [66-68]. 
Treatment with glucocorticoids reduced risk of respiratory failure and death in a controlled trial 
of 327 HIV patients [69]. Other anti-inflammatory medications are also being investigated to 
help control the rapid progression of respiratory failure, such as PDMP, a glycosphingolipid 
synthesis inhibitor, and Muromonab, an anti-CD3 T-cell depleting antibody [70, 71]. 
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1.3 THE IMMUNE RESPONSE 
1.3.1 Pulmonary Immunity and Disease 
The respiratory system is responsible driving oxidative metabolism through the exchange of 
carbon dioxide for oxygen. To efficiently do so, the trachea, bronchi, bronchioles, and alveoli 
form a tree-like organization in the lungs which provides a very large surface area (approx. 10 
m2 in healthy human adults) that can filter around 9,000 liters of air, daily [72]. This process is 
coupled by continuous bombardment with particulates, allergens, and microbes, which represents 
one of the largest immunological challenges for the host. The front line of defense is the 
epithelial barrier of the alveolar spaces which is lined by type-I and type-II epithelial cells. This 
innate host defense is managed by production of a mucus barrier, tight-junctions between cells, 
and anti-microbial peptides which all aid in ciliary clearance [73, 74]. Secretory cells such as 
goblet cells have relatively low numbers and minimal activity in normal airways but will 
increase during injury and infection. 
Mucins, large glycoproteins complexed with abundant O-linked polysaccharides, help 
create the mucus barrier which acts as a mucociliary escalator for the transport of pathogens out 
from the conducting airways. Mucins that are secreted, such as Muc5AC and Muc5B, can bind 
pathogens directly to prevent aggregation and binding to the epithelial surface. However, hyper 
production of mucus is characteristic of airway diseases, such as cystic fibrosis (CF), chronic 
obstructive pulmonary disease (COPD), and asthma. Mucus production is directly linked to Toll-
like receptor (TLR) signaling through IRF and NF-κB families and cytokine signaling via the 
Jak-Stat pathway [75, 76]. These TLR signals also lead to the successive production of anti-
microbial peptides, such as defensins, cathelicidin, surfactant proteins, and lysozyme, in addition 
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to chemokines and cytokines which recruit and activate innate and adaptive immune cells. The 
role epithelial cell-mediated immunity in the context of Pneumocystis infection has been largely 
understudied.  
 
1.3.2 Lung-Resident Dendritic Cells and Macrophages 
In order to form the appropriate and effective response to an infection, the lungs are monitored 
by an intricate network of sentinels known as dendritic cells (DCs). DCs can fall under a number 
of categories based on their origin and function, these include conventional (cDC), plasmacytoid 
(pDC), and monocyte-derived (moDC). In the lung, cDCs and moDCs can be identified by 
having high CD11c and MHC class II. cDCs can be further be distinguished by expression of 
CD103 or CD11b, in absence of the Fc receptor CD64. pDCs have intermediate CD11c and 
uniquely express high levels PDCA-1 and B-cell associated marker, B220. These subsets have 
their own distinct and overlapping functions, and are generally crucial for initiating immunity in 
response to a pathogen. DCs are typically located on the basolateral side of the alveolar 
epithelium, and project across the epithelial layer to sample antigens in the lumen [77-79]. 
Upon acquiring an immunogenic antigen, DCs migrate to the draining lymph nodes to 
induce T-cell and B-cell responses. This is performed through antigen presentation and 
costimulation through major histocompatibility complexes (MHCs). The two MHCs, MHC class 
I and MHC class II, function similarly in presenting peptides on the surface of the DCs, but 
present specifically to either CD8+ or CD4+ T-cells, respectively. Typically, MHC class I 
molecules acquire their processed antigen from intracellular sources, thus they are the primary 
mechanism to mount immune responses against viruses, intracellular bacteria, and 
abnormal/mutant cellular proteins. Alternatively, MHC class II acquires antigens exogenously 
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thus mounting responses against extracellular pathogens and allergens. However, MHC class I 
can sometimes acquire exogenous antigens through a process termed cross-presentation, while 
MHC class II molecules can present cytosolic proteins degraded through autophagy [80]. For 
both MHC classes, antigen to peptide-bound MHCs can be broken down into six general steps: 
1) acquisition of antigenic protein or peptides, 2) ubiquitination of the antigen which directs 
them to 3) a degradation process into smaller peptides by proteasomes, 4) transport of peptides 
into the endoplasmic reticulum or endolysosomal compartments where they 5) bind MHC class I 
or MHC class II molecules, respectively, and 6) are finally transported to the cell surface to 
interact with T-cells.  
MHC class I molecules are ubiquitously expressed on all nucleated cells, unlike MHC 
class II molecules which are only expressed on “professional” antigen present cells (APCs) i.e. 
macrophages, B-cells, and DCs [81]. In addition to antigen presentation, professional APCs also 
provide costimulation to T-cells by engaging two classes of molecules on T-cells. The first class 
of costimulatory molecules includes CD28 and inducible T-cell costimulatory (Icos), which 
reduces the threshold for quantity and duration of MHC contact with T-cells required for 
activation. The second class which includes TNF receptor family member: CD40, OX-40, and 
CD27 provide further costimulation, and is believed to be regulated by class I costimulatory 
signals.  
There is some debate on what roles the different subsets of DCs. Conflicting evidence 
suggest that they may contribute to T-cell lineage and differentiation, while other data suggests 
that each may initiate either an acute or central memory response [82-85]. Briefly, CD11b+ 
cDCs are suspected to have a Th2 or Th17 bias when stimulated with an allergic or fungal 
antigen, respectively, while CD103+ cDCs bias towards Th1 or Th2. In the context of influenza, 
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CD103+ cDCs have been shown to have the ability to present antigens derived from apoptotic 
cells, and have enhanced MHC class I presentation compared to CD11b+ cDCs. Furthermore, 
CD103+ cDCs preferentially induce effector CD8+ T-cell responses while CD11b+ cDCs induce 
memory CD8+ T-cell responses. CD8α+ pDCs on the other hand have been shown to have 
regulatory role against harmless allergens, which may be mediated by the expression of Fas 
(CD95), which induces T-cell apoptosis.  Conversely, CD8α- pDCs have been shown to mediate 
hyper-responsiveness. CD103+ cDCs have also been shown to play a role in tolerance through 
mediation of regulatory T-cell differentiation. DC subtype and function studies are still a relevant 
topic of research, with many unanswered questions currently under investigation [82-85].  
Dendritic cells play an important role during Pneumocystis infection. Patients with 
dendritic cell deficiencies develop a primary immunodeficiency and may develop Pneumocystis 
pneumonia [86]. The Pneumocystis cell wall component, β-glucan, can directly induce dendritic 
cells to express costimulatory molecules such as B7-1/B7-2 and CD40 ligand (CD40L) [87]. 
CD4-depleted mice that receive antigen-pulsed bone marrow-derived (BM-) DCs are partially 
protected for P. murina infection. However, Pneumocystis is unique in the sense that DCs alone 
are not sufficient to induce a protective T-cell response, and that during natural infection B-cells 
play a critical role in antigen presentation and priming of CD4+ T-cells [88, 89]. It’s still not 
well understood, why B-cells specifically are required to fully prime CD4+ T-cells or why DCs 
alone are not sufficient.  
Macrophages also play a major role in lung immunity and can be divided into at least 
three different categories based on their localization. These include alveolar macrophages (AM) 
located in the luminal space of the alveoli, interstitial macrophages (IM) located in the 
parenchymal space between two adjacent alveoli, and bronchial macrophages located within the  
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Table 2. Dendritic cell and macrophage surface marker expression  
Surface 
Marker 
Macrophages Dendritic Cells 
Alveolar Interstitial Conventional Monocyte-
derived 
Plasmacytoid 
CD103+ CD11b+ 
CD103 + + +++ + - - 
CD11b + + + +++ +++ + 
CD11c +++ + +++ +++ +++ + 
CD207 - + - - - 
CD24 + + +++ ++ + + 
CD64 + - - - + - 
CLEC9A - - +++ - - - 
F4/80 +++ ++ + ++ +++ + 
Ly6C + + - - + + 
MerTK ++ - - + ++ - 
MHC class II + +++ +++ +++ +++ + 
PDCA-1 + - - - - +++ 
Siglec F +++ - - - - - 
Siglec H - - - - - +++ 
SIRPα + + - + + - 
Expression levels indicated from high (+++) to low (+) and absent (-).  
branches of the bronchi and bronchioles. In steady state, AMs comprise greater than 90% of the 
cellular compartment in alveolar spaces. However, with their low number, only a single AM can 
be detected for approximately every three alveoli. To fully monitor the alveolar spaces, AM 
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travel between alveoli through the connecting pores of Kohn [74, 90, 91]. AMs can be 
distinguished from IMs through their unique expression of Siglec-F. For complete description of 
markers defining macrophage and dendritic cell subsets refer to (Table 2) [74, 77, 82, 92-101]. 
Interstitial macrophages are believed to function as antigen presenting cells to interstitial 
lymphocytes, but there is evidence that they play an important role in tolerance by promoting T 
regulatory cell responses. AMs can also modulate immune responses by blocking DC-mediated 
T-cell activation and producing transforming growth factor-beta (TGF-β) in conjunction with 
retinol precursors. This process is dependent on antigen presentation by AMs, and occurs 
specifically in the lung. Stimulation of pattern recognition receptors such as TLR-4 can initiate 
the switch to an inflammatory response by the induction of IL-1, IL-6, and tumor necrosis factor 
(TNF) [102]. Numerous reports and publications have confirmed the importance of AMs in the 
host response to viral, bacterial, and fungal infections. AMs have been demonstrated to be able to 
phagocytose a variety of pathogens including Streptococcus, Mycobacterium, Pseudomonas, and 
Pneumocystis.  
AMs are currently believed to be the major player for clearance of Pneumocystis 
infection through phagocytosis of both the trophic (Figure 4) and cystic forms. AMs express 
Dectin-1, which allows them to recognize the β-1,3-glucan rich cell wall on the ascus. Dectin-1 
deficient mice are more susceptible to Pneumocystis infection than wild-type mice, while mice 
treated with recombinant Dectin-1-FC protein have reduced burden [103-106]. Macrophages are 
generally categorized as classically activated (M1) or alternatively activate (M2). Type-1 
cytokines such as IFN-γ are believed to promote the M1 phenotype while type-2 cytokines such 
as IL-4, IL-13, and IL-33 promote an M2 phenotype. They differ in the both their cytokine 
profiles and mode for bactericidal/fungicidal activity; M1 macrophages function through nitric 
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oxide synthase while M2 macrophages use arginase. Clearance of P. murina appears to be driven 
by alternatively activate macrophages, and data from this thesis corroborate those finding [107, 
108].  
 
Figure 4. Macrophage phagocytosis of Pneumocystis 
Transmission Electron Microscopy (TEM) of an alveolar macrophage (red star) in the process of phagocytosis of a 
Pneumocystis trophozoites (yellow arrows). 
1.3.3 T-Cell Mediated Immunity in the Lung 
Pneumocystis is an organism that requires an intact adaptive immune system involving both 
humoral and cellular responses to mediate clearance. Many cell types and immunological factors 
have been implicated in the protective and/or the pathological responses to infection, including 
T-cells, B-cells, macrophages, dendritic cells, eosinophils, neutrophils, and the cytokine and 
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chemokine signals that coordinate their specific roles. T helper cells, CD4+ T-cells, are the most 
associated with immunity to Pneumocystis infection. As previously mentioned, reduction in 
frequency below 200 cells per microliter blood is the threshold for risk. This correlation has been 
validated in numerous animal models from mouse to macaque, by means of CD4-depletion and 
genetic knockout studies. Upon infection, antigen presenting cells (APCs), typically DCs, bridge 
adaptive and innate immunity by migrating from the lung to the draining lymph nodes where 
they present the antigen to naïve T-cells. Based on the DC’s MHC class restriction, CD4+ or 
CD8+ T-cells are activated and primed to perform specific immunological functions. Migration 
to the lymph node is not critical to prime the immune response as demonstrated by 
Lymphotoxin-α-/- and Ccr7-/- mice which are deficient in lymph node formation and DC 
migration to lymph nodes, respectively [109, 110].  
Activated CD4+ T-cells can be subdivided based on transcriptional regulation and 
effector cytokines, these classically include: T helper 1 (Th1), T helper 2 (Th2), and T helper 17 
(Th17). Each of these subsets have unique differentiation signals, transcriptional regulation and 
effector cytokines (Table 3). Th1 cells are classified by their production of interferon-gamma 
(IFNγ), and differentiate in the presence of IL-12p40. Th1 cells are transcriptionally controlled 
by T-box transcription factor (T-BET) and signal transducer activator of transcription-4 
(STAT4), and are generally induced in response to intracellular pathogens such as viruses and 
Mycobacterium [111-116]. IFNγ can stimulate macrophages to induce nitric oxide synthesis and 
generate reactive oxygen species (ROS), which in part mediate clearance of pathogens. IFNγ can 
also act as an inhibitor to other T-cell lineage development and reduce superfluous pathological 
responses. Th2 cells are classified and differentiated by the primary cytokine they produce, IL-4. 
Transcriptionally regulated by GATA3 and STAT6, and are typically induced in response to 
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extracellular parasites such as helminths and house-dust-mites (HDMs). IL-4 not only acts as an 
autocrine for Th2 differentiation but also inhibits Th1 and Th17 differentiation, and promotes B 
cell maturation into plasma cells. Th2 cells also produce IL-13 which works which has many  
Table 3. CD4+ T-cell Subtypes 
 
T helper cell 
subset 
Transcriptional 
Regulation 
Differentiation Signals Effector 
Cytokine(s) Activation Inhibition 
T helper 1 Tbx21 
Stat1  Stat4 
 
IL12  IFNγ IL4 IFNγ 
T helper 2 Gata3   
Stat5  Stat6 
IL33  IL4 IFNγ, TGFβ IL4  IL5 
IL6  IL13 
 
T helper 17 Rorc  Rorα 
Stat3 
 
IL6  IL1β 
TGFβ  IL21 
IFNγ  IL4 IL17 (a/f) 
IL22 
 
T follicular helper Bcl6 
Stat3 
IL6  IL21 
CXCL13 
N/A IFNγ  IL4 
IL17 (a/f)  IL21 
 
T regulatory Foxp3 
Stat5 
IL2  TGFβ IL21  IL23 IL10  TGFβ 
 
overlapping functions as IL-4, but is critical for the induction of airway hyper-responsiveness, 
goblet cell metaplasia, and mucus hypersecretion. IL-5 is also involved in important Th2 
functions by mediating eosinopoiesis and function. Eosinophils, as well as mast cells, basophils, 
and macrophages can produce copious amounts of IL-4 and IL-13 further enhancing the Th2 
responses. However, an overreaction of Th2 signals can cause pathological conditions such as 
asthma and allergy. Epithelial-derived cytokines, such as thymic stromal lymphopoietin (TSLP), 
IL-25 (IL-17E), and IL-33, are also believe to play in important role in Th2 protective and 
pathological responses.    
Th17 cells, cleverly named, are classified by their signature cytokine, IL-17. 
Transcriptionally regulated by RAR-related orphan receptor-C (RORc) and STAT3, Th17 cells 
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differentiate in the absence of Th1 and Th2 cytokines and presence of IL-1, IL-6, IL21, IL-23, 
and TGF-β. IL-17 has an important role in immunity against extracellular microbes such as 
gram-negative bacteria and fungi. IL-17 receptor signaling is also important for G-CSF 
production, granulopoiesis, and neutrophil recruitment in response to bacterial infection. Th17 
cells also produce IL-22, which has also been shown to play important role on epithelial 
responses and recovery, during and post-infection.  
Another class of T helper cells are regulator T cells (Treg), which can dampen the 
immune response through the production of IL-10. Tregs can be derived thymically and are 
referred to as natural (nTregs), but they can also be induced (iTregs) under the stimulation of 
TGFβ, retinoic acid, and high levels of IL-2. They have a transcription upregulation of forkhead 
box P3 (FOXP3) and STAT5 transcription factors. Defects in Treg function can lead to 
development of autoimmune disorders such as IPEX (immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome), while certain cancers and pathogens may 
stimulate Tregs to evade the immune response [117, 118]. Tregs play a crucial role in lung 
immunity in order to ensure maintenance respiratory function during immunological responses to 
allergens and pathogens. Another, somewhat controversial, subset of T helper cells is the T 
follicular helper cell (Tfh), named after its localization to germinal centers. Expression of Cxcr5 
on CD4+ T-cells draws them toward Cxcl13 expressing germinal centers which are composed of 
T-cells, B-cells, macrophages, and dendritic cells. Tfh cells help with B-cell activation and class-
switched antibody production, primarily through the production of IL-21. However, Tfh cells 
have also been characterized to mimic Th1, Th2, and Th17 responses. Whether Tfh cells are a 
unique lineage or a phenotypic state of  Th1, Th2, and Th17 cells is still under debate [119].   
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In the context of Pneumocystis infection, it is still unknown which T helper cell subset 
and effector function mediates protection. Various studies have shown recruitment of all three T 
helper cell subsets during Pneumocystis infection in various models [120]. Macaques infected 
with simian HIV (SHIV) upregulated Th2 cytokines upon Pneumocystis colonization [121]. 
Some studies have shown worsened Pneumocystis pneumonia in IFNγ-deficient mice, while 
other studies have shown neutralization of IL-17 and IL-23 leads to worsened infection [122]. In 
many of these studies, mice merely display transient or delayed clearance, so there is speculation 
whether Pneumocystis is a true opportunist that can be clear with any individual subset, or 
perhaps a unique unidentified subset is involved.  
On the other hand, CD8+ T-cells have a more questionable role during infection. Also 
referred to as cytotoxic T-cells, from their release of cytotoxic molecules such as granzyme and 
perforin, CD8+ T-cells are key producers of IL-2, IFNγ, and TNF-α. Although, CD8+ T-cells do 
accumulate in the long run during Pneumocystis infection, however, CD8+ T-cell deficiency 
does not lead to susceptibility [123]. Several other studies have shown that CD8+ T-cells influx 
in the long does not impact severity of disease [124-126]. However, few studies have shown that 
CD8+ T-cells may have a protective role, such as depletion of CD8+ T-cells in addition to CD4-
depletion exacerbates burden. Also, IFNγ treatment showed enhanced protection that was 
conferred by type 1 cytotoxic CD8+ T-cells through macrophage-mediated clearance [127, 128]. 
Although γδ T-cells are not implicated in clearance, some research suggest that they may play a 
role in managing the inflammatory pathology [129].  
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STATEMENT OF PURPOSE 
Pneumocystis is an opportunistic fungal pathogen that is considered a global health issue to HIV-
positive and non-HIV immunocompromised populations. It has been shown that prophylaxis of 
at risk patients can reduce the incidence of infection, severity of disease, and mortality rate in 
immunocompromised patients. However, TMP/SMX, the primary prophylactic drug, is relatively 
toxic, and only prescribed to defined at risk populations. Anti-CD20 monoclonal antibodies were 
originally used in treatment of chemotherapy-resistant B-cell non-Hodgkin lymphomas, but since 
then it’s also used therapeutically against hematological malignancies, autoimmune diseases, and 
post-transplant lymphoproliferative disease. Studies have shown that up to 30% of patients 
receiving Rituximab develop Pneumocystis pneumonia, however, there is debate as to the precise 
role anti-CD20 has in conferring risk. Many of these patients are also on concomitant 
immunosuppressive drugs, thus complicating any analyses of clinical studies. The first aim of 
this dissertation is to demonstrate that anti-CD20 therapy induces susceptibility to Pneumocystis 
infection, and that patients receiving this treatment should be categorized as an at-risk 
population.  
The predominant factor required for immunity against Pneumocystis infection is the 
presence of CD4+ T-cells. This has been validated several times over by clinical data and 
experimental animal models. Early on, studies have examined the role of T helper 1 (Th1), T 
helper 2 (Th2), and T helper 17 (Th17). To briefly summarize these studies, Th1, Th2, and Th17 
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cells can all be detected in the lung during infection, however, removal of their classically 
defined effector molecules, at most, only delayed clearance. Our goal in the second part of this 
study is to dissect the exact CD4+ T-cell signals that are required initiate a protective immune 
response, and identify the factors that mediate clearance. Understanding the exact immunological 
response will aid in the development of safer and more effective prophylaxis and treatments 
against Pneumocystis infection. 
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2.0  CHAPTER TWO: ANTI-CD20 THERAPY AND SUSCEPTIBILITY TO 
PNEUMOCYSTIS PNEUMONIA 
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2.1 INTRODUCTION 
2.1.1 Anti-CD20 Therapy 
CD20 is a B-lymphocyte antigen encoded by a membrane-spanning 4A family member, MS4A1. 
There is no known ligand for CD20; however it is believed to play a role in B-cell development 
and differentiation into plasma cells and T-cell independent antibody responses [130]. In 1997, 
anti-CD20 monoclonal antibodies were shown to be efficacious in treatment of chemotherapy-
resistant B-cell non-Hodgkin lymphomas [131, 132]. Since then the use of anti-CD20 has been 
used therapeutically against a broad range of conditions, including hematological malignancies 
such as lymphatic leukemia, autoimmune diseases such as rheumatoid arthritis, and post-
transplant lymphoproliferative disease. With the increased use of anti-CD20 as treatment over 
the years, there have been a number of reports of patients who have received anti-CD20 therapy 
that have subsequently developed a potential fatal pneumonia by Pneumocystis jirovecii [133]. In 
a study, Martin-Garrido found that Pneumocystis pneumonia developed in approximately 30% of 
patients receiving Rituximab (human anti-CD20 antibody), with a mortality rate as high as 30% 
[134]. However, there is debate as to the precise role anti-CD20 has in conferring risk to 
Pneumocystis infection as many of these patients are also on concomitant immunosuppressive 
drugs, thus complicating any analyses of clinical studies [134-136] 
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2.1.2 B-cells and Pneumocystis Infection 
The importance of B-cells was first observed when it was demonstrated that B-cell deficient 
mice (μMT-/-) were susceptible to Pneumocystis infection. At the time, this effect was suggested 
to be due to the lack of serum immunoglobulins, however, mice deficient in Fcγ receptor can 
clear infection [137]. Subsequent studies demonstrated that B-cells play a larger role than just 
antibody generation, as Lund et al. showed that B-cells were required for priming of CD4+ T-
cells and generating protective effector and memory CD4+ T-cells in response to Pneumocystis 
infection in mice [88]. This was demonstrated in both μMT-/- mice and MHC class II/μMT 
chimeras. Briefly, irradiated μMT mice received a 3:1 ratio of μMT:WT, μMT:MHCII-/-, or 
μMT:μMT bone marrow which forms a largely WT hematopoietic compartment with wild-type 
B-cells, MHC class II knockout B-cells, or B-cell deficient, respectively [88, 89]. They 
demonstrated that mice with MHC class II deficient B-cells were susceptible to infection, and 
this was attributed to a CD4 intrinsic defect. This suggests that depletion of CD20+ B-cells 
would also lead to CD4+ T-cell dysfunction and susceptibility to Pneumocystis infection. To 
experimentally test this hypothesis, we administered a murine anti-CD20 depleting antibody 
(5D2) followed by subsequent infection with P. murina.  We found that administration of anti-
CD20 conferred susceptibility to primary Pneumocystis infection. 
2.1.3 Anti-CD20 Therapy and Immune Reconstitution Inflammatory Syndrome 
It has been reported that some patients receiving an anti-CD20 containing treatment regimens for 
lymphoma developed immune reconstitution inflammatory syndrome (IRIS) after receiving the 
last regimen of treatment [138].  Thus we next investigated the effects of CD20 depletion on the 
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development of IRIS in our murine model. We concluded that although the pathology/lung injury 
associated with CD4+ T-cell reconstitution was not influenced by the presence or absence of B-
cells, the ability of the CD4+ T-cells to mount a protective immune response against 
Pneumocystis murina was in fact dependent on CD20+ B-cells. CD20 depletion does not affect 
the recruitment of CD4 cells to the lung, but infected lungs have a reduced type II immune 
responses. This study sheds some light on how anti-CD20 treatment in patients may affect their 
ability to mount a defense against Pneumocystis, and it may be critical to monitor these patients 
for Pneumocystis jirovecii.    
2.2 MATERIALS AND METHODS 
2.2.1 Mice  
Six- to Eight- week-old wild-type C57BL/6J (WT), immunodeficient B6.129S7-Rag1tm1Mom/J 
(Rag1-/-), and B6.CB17-Prkdcscid/SzJ (SCID) mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). Immunodeficient B10:B6-Rag2tm1FwaIl2rgtm1Wjl (Rag2-/-Il2rγ-/-) were 
originally obtained from Taconic (Hudson, NY) then bred and maintained at the University of 
Pittsburgh Division of Laboratory Animal Resources (DLAR) Facility at Rangos Research 
Building of Children’s Hospital of Pittsburgh of UPMC.  Animals were housed in a pathogen-
free environment and given food and water by the DLAR ad libitum. All experiments were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee. 
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2.2.2 Pneumocystis Isolation, Inoculum and Antigen Preparation 
Pneumocystis murina organisms were administered by oral-pharyngeal delivery into Rag2-/-
IL2rγ-/- mice, propagated for 10-12 weeks in vivo, and isolated from mouse lung tissue, as 
previously described [139]. Briefly, Rag2-/-IL2rγ-/- with Pneumocystis pneumonia were 
sacrificed, and the lungs were aseptically harvested and frozen in 1ml of sterile Dulbecco’s 
phosphate buffered saline (PBS) at -80°C.  Too process the inoculum, frozen lungs were thawed 
and strained through a 70μm filter and pelleted by centrifugation (800xg, 10min, and 4°C). The 
pellet was resuspended in 1ml of PBS.  A 5μl aliquot was diluted 1:10 and heat-fixed on a slide, 
and stain with Hema-3 modified Wright-Giemsa stain (Fisher Scientific Pittsburgh, PA) followed 
by asci counting. Pneumocystis murina asci were quantified microscopically, and the inoculum is 
adjusted to 2x106 asci per ml. Mice are administered 100μl (2x105 asci) of the inoculum by oral 
pharyngeal aspiration as previously described [140]. Pneumocystis protein antigen was prepared 
by differential centrifugation of the inoculum as previously described, followed by sonication of 
1mg of inoculum per ml for 5 minutes [120]. 
 
2.2.3 Whole Lung Cell Preparation and Antigen Stimulation 
 Mice were infected with an inoculum of P. murina for 2 weeks.  At the time of euthanasia, mice 
were anesthetized by intraperitoneal injection of ketamine/xylazine cocktail and euthanized by 
exsanguination. Immediately after mice were perfused vascularly by 5ml of heparinized PBS 
injection into the right ventricle. The right superior and inferior lobes are then harvested, minced 
with razorblades, and digested in 5ml serum-free media with 2mg/ml collagenase for 90 minutes 
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in a 37°C shaking incubator. Cell suspension is then strained through a 70μm filter, then washed 
and resuspended in complete DMEM media. Red blood cells were then lysed with ammonium 
chloride solution, washed, resuspended in 5mls, and counted. 106 cells per well are plated on a 
96-well round bottom plate in complete DMEM media with 1μg/ml PC antigen and 20U/ml IL-
2. An aliquot from each group is taken for cell analysis by flow cytometry. Plated cells are 
stimulated at 37°C at 5% CO2 for 72 hours. Finally, supernatants are harvested for multiplex 
(Millipore) cytokine analysis on a Bioplex reader (Bio-Rad).  
 
2.2.4 Flow Cytometric Analysis 
106 single cells from mouse lung were stimulated with 50ng/ml PMA (Sigma) and 750ng/ml 
ionomycin (Sigma) for 5-6 hours. After 1 hour from the start of stimulation cell were given 
1μl/mL GolgiStop (BD Pharmingen, San Diego, CA) to block cytokine secretion. Cells were 
surface stained with TCRβ (PerCP-Cy5.5), CD4 (E450), CD8 (PE-Cy7), and B220 (APC-Cy7) 
for 15-30 minutes in PBS supplemented with 1% BSA. Cells were then fixed in 1% Formalin, 
and acquired for flow cytometry by an LSR-II (BD Biosciences, San Jose, CA) and data was 
analyzed using FlowJo (Treestar). 
 
2.2.5 RNA Isolation and Pneumocystis Quantification by RT-PCR 
 The right middle lobe of the lung is harvest in 1ml of Trizol and homogenized. RNA is purified 
and quantified has previously described [139]. Briefly, cDNA was synthesized from 1μg whole 
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lung RNA via iScript reverse transcription reagents (Bio-Rad, Hercules, CA), and real-time PCR 
was performed using primers and probes for Pneumocystis murina large-subunit rRNA (LSU) 
transcript with SsoFast/SsoAdvanced Probes Supermix (Bio-Rad). The threshold cycle values 
were converted to copy number using a premade standard of known Pneumocystis LSU rRNA, 
as previously described [141]. 
2.2.6 Serum Collection and Pneumocystis murina Antigen ELISA 
 Blood was collected either periodically by tail-bleed and/or at time of sacrifice by syringe from 
the vena cava. Coagulated blood was then centrifuged for 10 minutes at 10,000xg. The serum 
supernatant was collected and stored at -80°C. Maxisorb plates are coated with 1μg P. murina 
antigen in 100μl bicarbonate coating buffer per well overnight at 4°C. Plates were blocked with 
5% blotting grade blocker (Bio-Rad) and 1% BSA. Plates were first primary stained with sample 
serum in a dilution series from 26 to 213 overnight at 4°C, then secondary stained with murine 
Ig-specific-HRP antibodies. Plates were then developed with TMB substrate for 5-30 minutes 
depending on control serum, and reaction stopped with equal volume 2N H2SO4. OD450 is read 
using Synergy H1 Hybrid Reader (BioTek Winooski, VT). 
 
2.2.7 Antibody Mediated Cell Depletion  
CD4+ cells were depleted using an anti-CD4 monoclonal antibody, GK1.5, as previously 
described [139]. Mice were injected in the intraperitoneal space weekly with 0.3mg dose of Ab 
in 200μl sterile PBS. CD4+ cell depletion efficiency is assessed by flow cytometry with anti-
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CD4, clone RM4-5, which does not compete with GK1.5. CD20+ cells are depleted using a 
mouse anti-mouse CD20 monoclonal antibody (Genentech, clone 5D2, isotype murine IgG2a). 
Mice were given intraperitoneal injections with 0.1mg doses of Ab every 5 days. CD20+ cell 
depletion efficiency is assessed by flow cytometry with anti-B220.  
 
2.2.8 Preparation of Splenocyte, Purified-CD4, and Purified-B220 Cells for Adoptive 
Transfer  
Spleens are harvested from C57BL/6J mice were harvested, diced, and strained through a 70μm 
filter for a single cell splenocyte suspension. CD4+ cells and B220 cells were purified using 
Stem Cell EasySep Negative Selection- Mouse CD4+ T-cell Isolation Kit and Mouse B220 B-
cell Isolation Kit, respectively. Cells were enumerated and resuspended in sterile PBS. Cells 
were resuspended at 2.5x106 cells/ml, and each mouse received 5x105 cells (200μl) via 
intravenous (tail-vein) injection. In testing CD4 capacity for clearance, mice were adoptively 
transferred 2 weeks prior to infection and sacrificed 4-6 weeks after infection with Pneumocystis 
murina. To induce immune reconstitution syndrome, mice were originally infected for 21 days 
prior to cell adoptive transfer, and then sacrificed 10 days after transfer.  
 
2.2.9 Pulse Oximetry and Lung Injury Qualification from BALF 
CD4+ cells were depleted using an anti-CD4 monoclonal antibody, GK1.5, as previously 
described [140]. Mice were injected in the intraperitoneal space weekly with 0.3mg dose of Ab 
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in 200μl sterile PBS. CD4+ cell depletion efficiency is assessed by flow cytometry with anti-
CD4, clone RM4-5, which does not compete with GK1.5. CD20+ cells are depleted using a 
mouse anti-mouse CD20 monoclonal antibody (Genentech, clone 5D2, isotype murine IgG2a). 
Mice were given intraperitoneal injections with 0.1mg doses of Ab every 5 days. CD20+ cell 
depletion efficiency is assessed by flow cytometry with anti-B220. 
2.2.10 Statistical Analysis 
Graphpad Prism (GraphPad Software, La Jolla, CA) one-way analysis of variance (ANOVA) 
with a HolmSidak multiple comparison post-test to calculate P values. Nonparametric data with 
three or more groups were analyzed with Kruskal-Wallis test with Dunn multiple comparison 
post-test. Two group comparisons were done with multiple t test. P values are annotated as 
follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. 
2.3 RESULTS 
2.3.1 Anti-CD20 Treatment Induces Susceptibility To Pneumocystis 
First, we independently validated that 5D2 (murine anti-CD20) was capable of depleting B-cells 
in mice. Prior to depletion (Day 0), over half of the splenocytes are IgM+, and the majority of 
which are also CD23+. By Day 6 post depletion, this population of cells is reduced by 
approximately 90% (Figure 5A). To investigate if anti-CD20 conferred susceptibility to primary 
Pneumocystis infection, we administered anti-CD20 to mice followed by Pneumocystis murina  
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Figure 5. Anti-CD20 treatment during Pneumocystis infection 
(A) Flow cytometry of whole splenocytes from untreated mice (left panels) and mice 6 days post treatment (right 
panels). Upper panels Y-axis (CD3) and X-axis (IgM). Lower panels are gated on the IgM+ and CD3- quadrant of 
upper panels; Y-axis (CD23) and X-axis (CD5). Representative images of n=3 per treatment were shown. (B) 
C57Bl/6 mice were depleted 2 days prior to infection and were treated with 5D2 every 7 days.  Mice were sacrificed 
2 and 4 weeks post infection. (C) Total lung RNA was isolated and Pneumocystis burden was measured by real-time 
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PCR of the mitochondrial Large Subunit rRNA copy number. Burden is reported as means + SEM for n = 4 per 
group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. 
Elsegeiny and K. Chen. 
 
infection (Figure 5B).   We measured P murina burden at both two and four weeks after 
infection, and at two weeks, 5D2 treated mice and isotype control mice had no differences in 
infectious burden. However, 4 weeks after infection, control mice began clearing infection 
whereas 5D2 treated mice had approximately a two log greater P murina burden in the lung 
(Figure 5C). Thus, CD20+ cells are crucial for a protective immune response and depletion 
results in high susceptibility to primary Pneumocystis infection. 
2.3.2 CD20 depletion blocks type 2 immune responses in the lung.   
To determine mechanisms by which anti-CD20 was permissive for sustained Pneumocystis 
infection, we assessed cellular immune responses in whole lung cells (WLC).  We harvested 
lungs from 5D2 treated, GK1.5 treated (CD4 depleted), and isotype control mice 2 weeks after 
infection. We chose two weeks because the infection load is approximately equal among all the 
groups, so any difference in immune responses could not be attributed to the presence of more 
antigen in vivo (Figure 6A). The lungs were digested and strained to generate WLC cultures that 
were analyzed by flow cytometry or stimulated with P. murina antigen. Total WLCs were 
counted so that absolute lymphocyte count could be calculated. There was no difference in the 
number of recovered WLCs; however, there was a significant reduction in the total lymphocyte 
count in CD20 depleted animals (Figure 6B,C).  Furthermore, flow cytometry analysis showed 
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that there was 98% CD4 depletion with GK1.5 administration and approximately 90% B220 
depletion with 5D2 (Figure 6D).   
 
Figure 6. CD4 and B220 cell assessment post anti-CD20 treatment 
(A) C57Bl/6 mice were administered anti-CD20 or control and infected with Pneumocystis for 2 weeks. Total lung 
RNA was isolated and Pneumocystis burden was measured by real-time PCR of the mitochondrial Large Subunit 
rRNA copy number. (B) Whole lung cells (WLCs) were counted from right superior and inferior lobes.  The 
absolute lymphocyte count was determined from the % lymphocyte gate (based on FSC and SSC) and the total lung 
WLC count. (C) Similarly, CD4 and B220 absolute counts were calculated by % positive cells and the absolute 
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lymphocyte count.  All data are reported as means + SEM for n = 5 per group. P values are annotated as follows (*) 
≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny. 
 
After stimulation of WLCs with P. murina antigen for 72 hours, we analyzed effector 
cytokines in cell supernatants by Luminex.  IFNγ production by WLCs did not differ across the 
groups (Figure 7A). IL17a was not highly produced and although there was trend to have higher 
levels in control mice, this was not statistically significant different between the groups (Figure 
7B). However, the vehicle control group had a strong type II signature, which was substantially 
reduced in both CD4 and CD20 depleted groups.  Briefly, IL-4 and IL-13 were substantially 
reduced in both CD4 and CD20 depleted samples. Although IL-5 expression was also reduced 
after CD20 depletion, levels were still significantly higher than the CD4 depleted samples 
(Figure 7C). However, depleting CD4+ cells from CD20 depleted mice further reduced type II 
responses, and were equivalent to levels of CD4 depletion alone. These data show that CD20 
depletion leads to a defect in effector immune responses in the lung, and that the decrease is 
primarily in type II immunity of whole lung cells.  
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Figure 7. Cytokine analysis of supernatants from Pneumocystis antigen stimulated WLCs 
WLCs were cultured in the presence of P. murina antigen and IL-2 for 72 hours. (A-C) All cytokines were analyzed 
simultaneously by Millipore multiplex on a bioplex reader. All data are reported as means + SEM for n = 5 per 
group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. 
Elsegeiny 
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2.3.3 Anti-CD20 treatment eliminates CD4+ T-cell protective responses.  
To address whether CD20 depletion alters specifically CD4 effector function, we then examined 
whether adoptively transferring purified CD4+ T-cells from naïve C57BL/6J WT mice into 
Rag1-/- had any protective effects against Pneumocystis.  Adoptive transfer of purified CD4+ T-
cells resulted in significant reductions in P. murina lung burden compared to vehicle control 
mice (Figure 8).  
 
Figure 8. Adoptive transfer of naïve CD4+ cells 
protects Rag1-/- from P. murina infection 
Naïve CD4+ cells were adoptively transferred into 
Rag1-/- mice. After homeostatic proliferation, mice 
were infected with P. murina for 4 weeks Total lung 
RNA was isolated and Pneumocystis burden was 
measured by real-time PCR of the mitochondrial 
Small Subunit rRNA copy number. Burden is 
reported as means + SEM for n = 4/5 per group. 
Contributors: W. Elsegeiny. 
 
We next examined if CD4+ T-cells from 5D2 treated mice or isotype control mice could 
clear Pneumocystis.  Briefly, 5D2 treated C57BL/6J WT mice were infected with the standard 
inoculum of Pneumocystis murina for 2 weeks. After which, CD4+ cells from these mice were 
purified and adoptively transferred to Rag1-/- mice (Figure 9A). Splenic CD4+ T-cells were also 
tested for their capacity to respond to CD3/CD28 bead stimulation ex vivo. CD4+ T-cells from 
CD20 depleted mice had significantly less IFNγ production and a trend for decreased IL-5 
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(Figure 9B). The cells were given 14 days to homeostatically proliferate in Rag1-/- mice before 
infecting with Pneumocystis murina.  Lungs were harvested at four weeks after infection and 
analyzed for P. murina burden.  Adoptive transfer of lung CD4+ T-cells from control mice again 
resulted in control of P. murina infection whereas lung CD4+ T-cells from CD20 depleted mice 
were defective in clearing P. murina (Figure 9C).  This could be result of clonal deletion or 
anergy to Pneumocystis antigen during infection of CD20-depelted mice.  
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Figure 9. Loss of CD4+ cell specific protection after anti-CD20 treatment 
(A) Mice were CD20 depleted and infected for two weeks with P. murina. Splenic CD4+ cells were then purified 
and adoptively transferred into Rag1-/- mice. After homeostatic proliferation, mice were infected with P. murina for 
4 weeks. (B) Purified splenic CD4+ cells from CD20 depleted mice were stimulated with CD3/CD28 beads. 
Cytokines in the supernatants were analyzed simultaneously by Millipore multiplex on a bioplex reader. (C) Total 
lung RNA was isolated and Pneumocystis burden was measured by real-time PCR of the mitochondrial Large 
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Subunit rRNA copy number. Burden is reported as means + SEM for n = 5 per group. P values are annotated as 
follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny. 
 
2.3.4 Mice with convalescent immunity are resistant to anti-CD20 mediated susceptibility.   
We next determined if anti-CD20 conferred risk to a secondary infection with P. murina.   To 
examine this, we generated convalescent mice by infecting them with P. murina and allowing 
them 8 weeks to clear and recover from the infection.  After the recovery period, one group was 
given 5D2, another group received GK1.5, and another group received carrier control (sterile 
PBS).  All groups were then reinfected with the same inoculum of P. murina, and fungal burden 
was measured 2 weeks after the second infection (Figure 10A).  All groups, including the CD4 
and CD20 depleted groups completely eradicated the infection (Figure 10B).  We wanted to 
discern the method of clearance, so we assessed the level of Pneumocystis murina specific 
antibodies in the serum. All groups had approximately equal levels anti-P murina IgG (Figure 
10C). We attributed the clearance to the presence of anti-Pneumocystis IgG.  To formally test 
this we examined the effector activity of these antibodies by adoptively transferring 200μl of 
either naïve or convalescent serum, from WT C57Bl/6 mice infected with P. murina, to Rag1-/- 
mice which lack T and B-cells (Figure 10D). Rag1-/- mice that receive convalescent serum were 
protected from infection (Figure 10E).  These studies show that anti-CD20 does not confer 
susceptibility to infection in the presence of pre-existing Pneumocystis immunity.  
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Figure 10. Humoral immunity is sufficient for protection against Pneumocystis 
(A) Wild-type C57Bl/6 mice were infected with P. murina and allowed to convalesce for 6 weeks. They were then 
CD20 depleted and infected with P. murina for 2 weeks. (B) Total lung RNA was isolated and Pneumocystis burden 
was measured by real-time PCR of the mitochondrial Large Subunit rRNA copy number. (C) Total P. murina 
antigen specific IgGs were measured by direct ELISA of a 1 to 64 dilution of serum as primary and anti-mouse IgG-
HRP secondary. (D) Serum harvested from convalescent mice were adoptively transferred into Rag1-/- at time of 
infection with P. murina. (E) Pneumocystis burden following transfer of convalescent serum as measured by real-
 49 
time PCR as described above. All data are reported as means + SEM for n = 3 to 5 per group. P values are annotated 
as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny. 
2.3.5 B-cells are dispensable during T-cell immune reconstitution inflammatory 
syndrome (IRIS). 
We next determined if CD20+ cells may contribute to IRIS. The first model we used to test this 
experiment was using severe combined immune deficient (SCID) mice infected with 
Pneumocystis murina followed by adoptive transfer of whole splenocytes to induce IRIS [142]. 
As a negative control for IRIS in this experiment, a group of SCID mice received whole 
splenocytes and were depleted of CD4+ T-cells in vivo. We then examined whether or not anti-
CD20 reduced or prevented tissue pathology (Figure 11A). We first measured weight and found 
that mice that received anti-CD20 lost approximately the same percent of total body weight as 
the non-depleted (Figure 11B).  However depletion of CD4+ T-cells prevented weight loss.  
Total protein in the BAL, a measure of lung damage, was also significantly reduced in mice that 
received anti-CD4 antibodies but increased in control and anti-CD20 treated mice (Figure 11C). 
Lactate dehydrogenase activity in the BAL, a measure of cell death in the lung, was elevated in 
mice that received whole splenocytes but was significantly abrogated in mice that received anti-
CD4 (Figure 11D). However there was slightly greater LDH activity in mice that received anti-
CD20.  These data show that IRIS requires CD4+ T-cells but anti-CD20 had little effect on the 
development of IRIS in this model.    
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Figure 11. Influence of CD20 depletion on Immune Reconstitution Inflammatory Syndrome 
(A) Balb/c SCID mice are infected with P. murina for 3 weeks, then reconstituted with WT splenocytes + CD20 or 
CD4 depletion for 10 days. (B) Mice were weighed before and after reconstitution to determine percent weight loss. 
(C) Total protein from BALF was measured by BCA assay. (D) Lactate dehydrogenase in the BAL was measured 
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by a kinetic assay of LDH activity. All data are reported as means + SEM for n = 5 per group. P values are annotated 
as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny and T. Eddens. 
We next examined if CD20+ cells in conjunction with CD4+ T-cells affected IRIS.   We 
also tested the hypothesis that Pneumocystis-experienced B-cells or plasma cells would provide a 
protective effect and mitigate IRIS.  Briefly, we adoptively transferred CD4+ T-cells alone, 
CD4+ T-cells plus B220 cells from naïve mice, or CD4+ T-cells plus B220 cells from antigen 
experienced (Ag Exp) mice into P. murina infected Rag1-/-.  Ag Exp cells were from mice 
infected with Pneumocystis murina for 14 days. We sacrificed mice at day 10 post transfer, as at 
this time point Pneumocystis burden is still equal between all the groups (Figure 12A) but is the 
peak day of lung injury. By day 10 we could detect anti-chitin IgM levels in the serum of the 
naïve and antigen experience B220 cell transferred mice, and anti-Pneumocystis IgG levels only 
in the Ag Exp B220 cell transfer (Figure 12B,C). Like the previous experiment, adding B220 
cells, naïve or Ag Exp, did not affect weight loss, blood oxygen saturation, or BALF lactate 
dehydrogenase (Figure 12D-F).  These data show that B-cells are dispensable for CD4+ T-cell 
mediated IRIS in this model.  
 52 
 
Figure 12. Influence of naïve and antigen-experienced B220 cells on IRIS 
(A) Total lung RNA from mice reconstituted with a combination of CD4+ T-cells plus naïve or antigen experienced 
B220 cells were isolated and Pneumocystis burden was measured by real-time PCR of the mitochondrial Large 
Subunit rRNA copy number. (B and C) Anti-Chitin-IgM and anti-P. murina-IgG in serum were assessed by direct 
ELISA with anti-IgM and anti-IgG secondary HRP antibodies, respectively. (D) Mice were weighed before and after 
reconstitution to determine percent weight loss. (E) Mouse blood oxygenation was measured immediately prior to 
sacrifice, by pulse-oximeter. (F) Lactate dehydrogenase in the BAL was measured by a kinetic assay of LDH 
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activity. All data are reported as means + SEM for n = 4 or 5 per group. P values are annotated as follows (*) ≤0.05, 
(**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny and T. Eddens 
2.4 DISCUSSION  
As there is an increase in the number of incidents of opportunistic infections involving patients 
receiving anti-CD20-containing treatment regimens, there is a need to understand the effects of 
anti-CD20 on the immune response to infection. We pursued this question by developing an in 
vivo mouse model of CD20-depletion in an attempt to recapitulate the clinical scenario of anti-
CD20 treatment. We were first able to observe that anti-CD20 alone was capable of inducing 
susceptibility to Pneumocystis infection by diminishing the immune response to Pneumocystis in 
the lung. WLCs showed reduced type 2 responses and CD4+ T-cells specifically were not 
capable of providing protective responses in an adoptive transfer model.  These data suggest that 
anti-CD20 inhibits T-cell priming to P. murina. [143].  As such, CD4+ T-cells appear to recruit 
eosinophils early in infection while B cells are undergoing and provide preliminary control of 
Pneumocystis burden. Importantly, IL-5 transcription and eosinophil recruitment appears to be 
dependent on CD4+ T-cells in this model, as such markers do not appear until after activation of 
the adaptive immune response at day 7 post-infection (refer to Appendix A).  
Eosinophils, classically recognized as mediators of immunity against helminths, have 
recently been implicated in host defense against a variety of pathogens, including bacterial and 
viral infections [144]. Recently, we have demonstrated that eosinophils contribute to host 
defense against the fungal pathogen Aspergillus fumigatus through a secretory factor, as 
eosinophils could mediate fungal killing when separated using transwells [145]. The study in 
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Appendix A extends these findings by demonstrating that eosinophil-deficient mice are more 
susceptible to Pneumocystis infection and that eosinophils display antifungal activity in vitro. 
Additionally, treatment of bone marrow derived eosinophils with IL-4 and IL-13 greatly 
enhanced killing of Pneumocystis, suggesting that Th2 cytokines in the lung may augment 
eosinophil-dependent antifungal activity (refer to Appendix A). 
It is still not known why specifically CD20+ B-cells are required to prime CD4+ cell 
responses to Pneumocystis. Previous studies that have shown that both CD40 and MHC class II 
on B-cells are critical for the CD4+ T -cell priming; however, why other antigen presenting cells 
were not capable is still a question that needs addressing [89]. Interestingly, the absence of 
CD20+ cells during Pneumocystis infection may lead to clonal deletion of Pneumocystis specific 
CD4+ cells since they are not as capable of clearing Pneumocystis as CD4+ cells from naïve 
mice. This may be due to a lack of CD4+ T-cell costimulation by B-cells during Pneumocystis 
infection.  
While the previous experiments were conducted in naïve mice, anti-CD20-treated 
patients are likely not naïve to Pneumocystis jirovecii, as most individuals are seropositive for 
anti-Pneumocystis antibodies [120, 146].  It is still unknown what the potential reservoirs are for 
Pneumocystis, but some research indicates the possibility that many diseased and healthy 
patients may be colonized with Pneumocystis. Some studies also suggest that hosts may be 
transiently exposed or asymptomatically carry Pneumocystis throughout their lives [147]. We 
observed that convalescent mice were capable of clearing Pneumocystis without the aid of CD4 
or CD20+ cells, most likely through antibody mediated protection. Since memory CD4+ cells 
and antibodies are enough to clear Pneumocystis, these data raise a question as to why 
immunosuppressed patients acquire Pneumocystis jirovecii infections. Anti-CD20 antibody 
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therapy in patients alone has not been shown to decrease immunoglobulin levels, however, when 
combined with other  immunosuppressive therapies hypogammaglobulinaemia can occur [148]. 
It has also been demonstrated that Pneumocystis spp have a dynamic extracellular proteome by 
varying their major surface glycoproteins, which may be used to evade the host immune 
response [149, 150]. Reports of large genetic variability between Pneumocystis jirovecii isolates 
also suggests the possibility that patients are simply being exposed to a new strain of 
Pneumocystis [143, 151]. 
Immune Reconstitution Inflammatory Syndrome (IRIS) is a condition that was first 
observed with the advent of highly active antiretroviral therapy (HAART), which dramatically 
suppresses HIV replication [152]. This suppression leads to an expedient reconstitution of CD4+ 
T-cells, which then react to an accumulation of viable infection and/or residual microbial 
antigens acquired during immunosuppression. As a result, the host can experience a massive 
amount of inflammation in multiple organs, primarily the lungs and CNS [153, 154]. This 
immunopathology is mediated through CD4+ T-cells [155], but it has been previously shown 
that other cell types such as CD8 cells modulate the pathology by increasing the Treg:Teffecor ratio 
[156]. Previous studies have shown that natural antibodies may reduce pathology [140]; 
however, the direct role of B-cells during IRIS has yet to be studied. Thus, as B-cells are 
required for T cell effector function in protection, we hypothesized that CD20+ cells may also 
play a role in the inflammatory pathology of T cell mediated IRIS. We observed that the absence 
or presence of CD20+ cells does not exacerbate the pathology in the model studied here. We 
hypothesize that this is due to CD4+ T-cell nonspecific activation through homeostatic 
proliferation.  Thus we conclude that CD20+ cells are dispensable in CD4 mediated IRIS.   
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Thus, in conclusion, anti-CD20 confers risk to primary infection with P. murina but we 
did not observe risk of secondary infection in mice that had pre-existing humoral immunity. In 
addition, mice treated with anti-CD20 had reduced whole lung cell type II responses to 
Pneumocystis, and CD4 cells from depleted mice had an intrinsic impairment in their ability to 
clear Pneumocystis in our adoptive transfer model. These data suggest that clinical Pneumocystis 
jirovecii pneumonia could be due to concomitant immunosuppression or patients are requiring 
antigenically distinct strains of Pneumocystis that pre-existing humoral immunity is ineffective 
in preventing.  Lastly anti-CD20 did not affect the severity of CD4 T-cell mediated IRIS in this 
model. 
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3.0  CHAPTER 3: CD4+ T-CELL INTRINSIC IL-21R SIGNALING AND THE 
FACTORS THAT MEDIATE PNEUMOCYSTIS CLEARANCE  
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3.1 INTRODUCTION 
The predominant factor required for immunity against Pneumocystis infection is the presence of 
CD4+ T-cells. The emergence of Pneumocystis pneumonia as an AIDS-defining infection 
established the direct correlation of CD4+ T-cell loss with susceptibility to infection. This role 
has been validated numerous times in a variety of animal models from murine to macaque. 
Restoration of CD4+ T-cells in otherwise deficient patients or animals also restores the immunity 
against Pneumocystis infection, which further demonstrating the importance of CD4+ T-cells. 
However, the exact mechanism in which CD4+ T-cells mediate clearance is still unclear. 
Early on, studies have examined the role of T helper 1 (Th1) and T helper 2 (Th2) 
lymphocyte subsets in murine and SHIV-macaque models of Pneumocystis infection, and 
concluded that both subsets could be observed in the lungs.  Particularly, Th2 cytokines, such as 
interleukin-4 (IL-4), IL-5, and IL13, were found to be upregulated in the BAL of macaques 
colonized with Pneumocystis [120, 157]. Th1 cytokines, such as interferon gamma (IFN-γ) and 
tumor necrosis factor alpha (TNF-α), were increased only when macaques began to develop 
active infection. Later, as T helper 17 (Th17) lymphocytes emerged as a unique subset, they were 
also characterized in the context of Pneumocystis infection. Interestingly, Th17 cells are also 
detectable in the lungs during Pneumocystis infection, however, mice deficient in Th17 
responses, such as IL-17 and IL-23, only have delayed clearance [158]. Our goal in the following 
study is to dissect the exact CD4+ T-cell signals that are required initiate a protective immune 
response, and identify the factors that mediate clearance. 
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3.2 MATERIALS AND METHODS 
3.2.1 Mice.  
Six- to Eight- week-old wild-type C57BL/6J (WT), Balb/C (WT), BALB/c-Il4ratm1Sz/J (Il4ra-/-), 
C.129S1-Il12btm1Jm/J (Il12b-/-), B6.129S7-Rag1tm1Mom/J (Rag1-/-), B6.CB17-Prkdcscid/SzJ 
(SCID), B6.129S2(C)-Stat6tm1Gru/J (Stat6), B6N.129-Il21rtm1Kopf/J, and B6.129S2(Cg)-
Cxcr5tm1Lipp/J (CXCR5-/-) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). 
B10:B6-Rag2tm1FwaIl2rgtm1Wjl (Rag2-/-Il2rγ-/-), Il17ratm1Koll (Il17ra−/−), B6.129-IL23p19tm1N12 
(Il23a-/-), and B6.IL22tm1 (IL22), B6.Cg-Tg(CD4-cre)1CwiN9 (CD4-Cre) mice on C57BL/6 
background were originally obtained from Taconic (Hudson, NY). Stat4-/- mice and Stat3fl/fl 
mice on C57BL/6 background were obtained from M.H. Kaplan. We also cross Stat4 to Stat6 to 
get Stat4/6 double KO mice and then crossed to Stat3fl/fl/CD4Cre mice to get Stat3/4/6 triple 
KO mice. B6.IL21-/- mice were obtained from Dr. Khader at University of Pittsburgh School of 
Medicine. Mice were then bred and maintained at the University of Pittsburgh Division of 
Laboratory Animal Resources (DLAR) Facility at Rangos Research Building of Children’s 
Hospital of Pittsburgh of UPMC. GM-CSF-/- splenocytes were provided by Dr. Z.C. Chroneos at 
PSU. Animals were housed in a pathogen-free environment and given food and water by the 
DLAR ad libitum. All experiments were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
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3.2.2 Pneumocystis Isolation, Inoculum and Antigen Preparation.  
Pneumocystis murina organisms were administered by oral-pharyngeal delivery into Rag2-/-
IL2rγ-/- mice, propagated for 10-12 weeks in vivo, and isolated from mouse lung tissue, as 
previously described [139]. Briefly, Rag2-/-IL2rγ-/- with Pneumocystis pneumonia were 
sacrificed, and the lungs were aseptically harvested and frozen in 1ml of sterile Dulbecco’s 
phosphate buffered saline (PBS) at -80°C.  To process the inoculum, frozen lungs were thawed 
and strained through a 70μm filter and pelleted by centrifugation (800xg, 10min, and 4°C). The 
pellet was resuspended in 1ml of PBS.  A 5μl aliquot was diluted 1:10 and heat-fixed on a slide, 
and stain with Hema-3 modified Wright-Giemsa stain (Fisher Scientific Pittsburgh, PA) followed 
by asci counting. Pneumocystis murina asci were quantified microscopically, and the inoculum is 
adjusted to 2x106 asci per ml. Mice are administered 100μl (2x105 asci) of the inoculum by oral 
pharyngeal aspiration as previously described [140]. Pneumocystis protein antigen was prepared 
by differential centrifugation of the inoculum as previously described, followed by sonication of 
1mg of inoculum per ml for 5 minutes [120]. 
3.2.3 Whole Lung Cell Preparation and Antigen Stimulation. 
 Mice were infected with an inoculum of P. murina for 2 weeks.  At the time of euthanasia, mice 
were anesthetized by intraperitoneal injection of ketamine/xylazine cocktail and euthanized by 
exsanguination. Immediately after mice were perfused vascularly by 5ml of heparinized PBS 
injection into the right ventricle. The right superior and inferior lobes are then harvested, minced 
with razorblades, and digested in 5ml serum-free media with 2mg/ml collagenase for 90 minutes 
in a 37°C shaking incubator. Cell suspension is then strained through a 70μm filter, then washed 
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and resuspended in complete DMEM media. Red blood cells were then lysed with ammonium 
chloride solution, washed, resuspended in 5mls, and counted. 106 cells per well are plated on a 
96-well round bottom plate in complete DMEM media with 1μg/ml PC antigen and 20U/ml IL-
2. An aliquot from each group is taken for cell analysis by flow cytometry. Plated cells are 
stimulated at 37°C at 5% CO2 for 72 hours. Finally, supernatants are harvested for multiplex 
(Millipore) cytokine analysis on a Bioplex reader (Bio-Rad).  
3.2.4 RNA sequencing 
Total RNA from mouse whole lung was used to perform RNA sequencing. Each sample was 
assessed using Qubit 2.0 fluorometer and Agilent Bioanalyzer TapeStation 2200 for RNA 
quantity and quality. Library preparation was done using Illumina TruSeq Stranded mRNA 
sample prep kit. The first step in the workflow involves purifying the poly-A containing mRNA 
molecules using poly-T oligo attached magnetic beads. Following purification, the mRNA is 
fragmented into small pieces using divalent cations. The cleaved RNA fragments are copied into 
first strand cDNA using reverse transcriptase and random primers. Strand specificity is achieved 
by using dUTP in the Second Strand Marking Mix, followed by second strand cDNA synthesis 
using DNA polymerase I and RNase H. These cDNA fragments then have the addition of a 
single 'A' base and subsequent ligation of the adapter. The products are then purified and 
enriched with PCR to create the final cDNA library. The cDNA libraries are validated using 
KAPA Biosystems primer premix kit with Illumina-compatible DNA primers and Qubit 2.0 
fluorometer. Quality is examined using Agilent Bioanalyzer Tapestation 2200.The cDNA 
libraries will be pooled at a final concentration 1.8pM. Cluster generation and 75bp paired read 
single-indexed sequencing was performed on Illumina NextSeq 500’s. 
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3.2.5 Flow Cytometric Analysis.  
106 single cells from mouse lung were surface stained with a combination of TCRβ (PerCP-
Cy5.5), CD3 (Pacific Blue), CD4 (PE or Pacific Blue), CD44 (APC-Cy7), CD62l (APC), CD69 
(Pe-Cy7), and CD127 (PE) for T-cell phenotyping; CD11b (PerCP-Cy5.5), CD11c (PE-Cy7), 
F4/80 (APC-Cy7), MHCII (APC), SiglecF (PE), Ly6G (FITC), and CD103 (Pacific Blue) for 
APC phenotyping. Cells were stained for 15-30 minutes in PBS supplemented with 1% BSA. 
Cells were then fixed in 1% Formalin, and acquired for flow cytometry by an LSR-II (BD 
Biosciences, San Jose, CA) and data was analyzed using FlowJo (Treestar). 
3.2.6 RNA Isolation and Pneumocystis Quantification by RT-PCR. 
 The right middle lobe of the lung was harvested in 1ml of Trizol and homogenized. RNA was 
purified and quantified as previously described [139]. Briefly, cDNA was synthesized from 1μg 
whole lung RNA via iScript reverse transcription reagents (Bio-Rad, Hercules, CA), and real-
time PCR was performed using primers and probes for Pneumocystis murina large-subunit rRNA 
(LSU) transcript with SsoFast/SsoAdvanced Probes Supermix (Bio-Rad). The threshold cycle 
values were converted to copy number using a premade standard of known Pneumocystis LSU 
rRNA, as previously described [141]. Quantification was also performed using primers and a 
probe specific for Pneumocystis murina small subunit (SSU) rRNA with a standard curve of 
known Pneumocystis SSU rRNA concentrations. SSU primer and probe sequences are as 
follows: Forward: 5’-CATTCCGAGAACGAACGCAATCCT; Reverse: 5’- 
TCGGACTTGGATCTTTGCTTCCCA; FAM-Probe: 5’- TCATGACCCTTATGGAGTGGG 
CTACA.   
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3.2.7 Serum Collection and Direct ELISA. 
 Blood was collected either periodically by tail-bleed and/or at time of sacrifice by syringe from 
the vena cava. Coagulated blood was then centrifuged for 10 minutes at 10,000xg. The serum 
supernatant was collected and stored at -80°C. Maxisorb plates are coated with 1μg/well of P. 
murina antigen, chitin, or GSC-1 in 100μl bicarbonate coating buffer per well overnight at 4°C. 
Plates were blocked with 5% blotting grade blocker (Bio-Rad) and 1% BSA. Plates were first 
primary stained with sample serum in a dilution series from 26 to 213 overnight at 4°C, then 
secondary stained with murine Ig-specific-HRP antibodies. Plates were then developed with 
TMB substrate for 5-30 minutes depending on control serum, and reaction stopped with equal 
volume 2N H2SO4. OD450 is read using Synergy H1 Hybrid Reader (BioTek Winooski, VT). 
 
3.2.8 Antibody Mediated Cell Depletion.  
CD4+ cells were depleted using an anti-CD4 monoclonal antibody, GK1.5, as previously 
described [139]. Mice were injected in the intraperitoneal space weekly with 0.3mg dose of Ab 
in 200μl sterile PBS. CD4+ cell depletion efficiency is assessed by flow cytometry with anti-
CD4, clone RM4-5, which does not compete with GK1.5.  
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3.2.9 Preparation of Purified-CD4+ T-cells for Adoptive Transfer.  
Spleens from control or experimental mice were harvested, diced, and strained through a 70μm 
filter for a single cell splenocyte suspension. CD4+ cells were purified using Stem Cell EasySep 
Negative Selection- Mouse CD4+ T-cell Isolation Kit. Cells were enumerated and resuspended 
in sterile PBS. Cells were resuspended at 2.5x106 cells/ml, and each mouse received 5x105 cells 
(200μl) via intravenous (tail-vein) injection. In testing CD4 capacity for clearance, mice were 
adoptively transferred 2 weeks prior to infection and sacrificed at 2, 4, or 6 weeks after infection 
with Pneumocystis murina.  
3.2.10 Histology 
The left main bronchus was clamped using forceps and 250μL of 10% formalin was injected into 
the bronchus. The lung tissue was then submerged in 10% formalin, paraffin-embedded, and 
processed by the Children’s Hospital of Pittsburgh Histology Core. Sections were then stained 
from H&E and PAS. 
3.2.11 Statistical Analysis.  
Graphpad Prism (GraphPad Software, La Jolla, CA) one-way analysis of variance (ANOVA) 
with a HolmSidak multiple comparison post-test to calculate P values. Nonparametric data with 
three or more groups were analyzed with Kruskal-Wallis test with Dunn multiple comparison 
post-test. Two group comparisons were done with multiple t test. P values are annotated as 
follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. 
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3.3 RESULTS 
3.3.1 Classical Th1, Th2, and Th17 effector cytokine signals are not required for 
Pneumocystis clearance.  
Initially, to understand which effector CD4+ T-cell signals are important for clearance of 
Pneumocystis during infection, we measured P. murina burden in wild-type and numerous 
different cytokine/receptor knockout mice. In a standard infection model, mice are infected with 
an inoculum of 2x105 asci for 4 weeks (Figure 13A). To assess the role of Th1 cells, IL-12p40 
knockout mice, which are deficient in IFN-γ production, were used, and IL4 receptor-α knockout 
mice were used as a model of impaired Th2 signaling. Both of these mice were able to 
completely clear infection comparable to wild type mice (Figure 13B). Next we examined the 
importance of Th17 cells by infecting IL-23α and IL-17 receptor-α knock out mice, and similar 
to the Th1 and Th2 deficient mice, Th17 effector responses also appeared to be dispensable 
(Figure 13C). However, these T helper cells can function through various non-classical signals, 
thus we decided to target the signal transducers and activators of transcription (STATs) of these 
subsets; Stat4, Stat6, and Stat3 which are critical for Th1, Th2, and Th17 differentiation, 
respectively. Global Stat4 and Stat6 knockout mice were acquired, and CD4-driven Cre+, Stat3 
floxed transgenic mice were used since global Stat3-deficiency is embryonically lethal. We also 
infected these mice with P. murina as previously described and examined burden. Stat4 and 
Stat6 knockout mice had delayed clearance of P. murina infection, however, Stat3fl/fl | CD4-Cre+ 
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mice were susceptible (Figure 13D). These data show that although the classical Th17 
cytokines, IL-17 and IL-23, are not critical for clearance, the key transcriptional activator for 
Th17 cells, Stat3, is required. 
 
Figure 13. Classical Th1, Th2, and Th17 factors are dispensable during P. murina infection 
(A) Diagram depicting the standard infection timeline with inoculation of P. murina defined as Day 0, and burden 
examined on Day 28. (B-D) Total lung RNA was isolated and Pneumocystis burden was measured by real-time PCR 
of the mitochondrial Large Subunit rRNA copy number. Burden is reported as means + SEM for n ≥3 per group. P 
values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. 
Elsegeiny, M. Zheng, and J. Alcorn. 
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We next were interested in examining the STAT knockouts in a CD4+ T-cell intrinsic 
model. To do so, we examined whether we could rescue Rag1 knockout mice through 
reconstitution of CD4+ T-cells. Rag1-/- mice have ablated T- and B-cell development, and are 
susceptible to P. murina infection. We purified splenic CD4+ T-cells from wild-type mice, and 
intravenously administered 5x105 cells into Rag1-/- mice, 2 weeks prior to infection (Figure 
14A). Mice that received wild-type CD4+ T-cells had approximately a log reduction in burden, 
while mice that received CD4+ T-cells from an OTII transgenic Rag1-/- mice showed no 
protection (Figure 14B). CD4+ T-cells from OTII transgenic Rag1-/- mice express can only 
express an OVA peptide specific TCR, thus are incapable of mounting an antigen specific 
response against any other epitope. Using this model, we verified that Stat3 knockout CD4+ T-
cells are intrinsically defective in generating a protective immune response to infection (Figure 
14C). However, to determine if Stat3 was exclusively required for clearance, we also generated 
Stat4/Stat6 double knockout (DKO) mice, and adoptively transferred DKO CD4+ T-cells into 
Rag1-/-. Surprisingly, these cells demonstrated enhanced clearance of Pneumocystis. The 
enhancement correlated directly to increased Stat3 function, assessed by a measured increase in 
IL-17a, IL-17f, and IL-22. Furthermore, when Stat3 was additionally knocked out, forming triple 
knockout (TKO), CD4+ T-cells lost the ability to control infection, showing that this 
enhancement is dependent on Stat3 signaling (Figure 14D). 
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Figure 14. CD4 intrinsic Stat3 required for clearance 
(A) Diagram depicting standard adoptive transfer protocol. Briefly, splenic CD4+ cells are purified from control and 
experimental mice, then adoptively transferred intravenously signifying Day 0. Mice are rested as cells 
homeostatically proliferate for 2 weeks. Mice are then infected for 4 weeks prior to endpoint readouts. (B-D) Total 
lung RNA was isolated and Pneumocystis burden was measured by real-time PCR of the mitochondrial Large 
Subunit rRNA copy number. Burden is reported as means + SEM for n ≥4 per group. P values are annotated as 
follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. DKO- double knockout (Stat4/Stat6). TKO- triple 
knockout (Stat4/Stat6/Stat3fl/fl|CD4-Cre+). Contributors: W. Elsegeiny; S. Khader provide IL-21-/- mice. 
Contributors: W. Elsegeiny and M. Zheng. 
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3.3.2 IL-21R signaling is necessary for control of Pneumocystis infection. 
Many cytokines and factors activate Stat3, such as interferons, growth factors, and various 
interleukins. IL-6 and IL-21 are considered two important immunological activators of Stat3 in 
CD4+ T-cells. IL-21 is also the signature molecule for T follicular helper cells, so we next 
examined the importance of IL-21 signaling during P. murina infection. We infected and 
measured burden in IL-21 and IL-21 receptor knockout mice at 2 and/or 4 weeks after infection 
(Figure 15A). At 4 weeks, both IL-21 and its receptor were shown to be critical for clearance 
(Figure 15B). We followed up by examining burden and other markers at both 2 and 4 weeks of 
infection. The adaptive immune response against Pneumocystis starts at two weeks of infection, 
so burdens are still equivalent. However, by week, 4 WT mice cleared 90 to 99 percent of the 
infection, while IL21 receptor knockout mice remained heavily burdened (Figure 15C). 
Furthermore, IL-21 receptor knockout mice showed no defect in Th1 transcription factor 
expression, Tbx21, or cytokine expression of IFN-γ (Figure 15D,E). They also had no defect in 
Th2 transcription factor expression, Gata3, or cytokine expression of IL-13 (Figure 15F,G). 
There was, however, a significant reduction the Th17 transcription factor expression, such as 
RORc and RORα expression (Figure 15H,I). 
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Figure 15. IL-21 signaling required for P. murina clearance 
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(A) Diagram depicting time-course infection model with inoculation of P. murina defined as Day 0, and burden 
examined on Day 14 and 28. Total lung RNA was isolated. (B-C) Pneumocystis burden was measured by real-time 
PCR of the mitochondrial Small Subunit rRNA copy number. (D-I) Gene expression was measured by real-time 
PCR, normalized to paired HPRT expression. Burden and gene expression are reported as means + SD for n ≥4 per 
group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. 
Elsegeiny; S. Khader provided IL-21-/- mice. 
3.3.3 IL-21 signaling is required for protective B- and T-cell responses. 
We also took a close look at the B cell responses in mice deficient of IL21 signaling. Although 
IL21 and IL21 receptor deficient mice have normal levels of natural antibodies, as measured by 
anti-Chitin IgM titers (Figure 16A), they have decreased IgG antibodies against whole 
Pneumocystis antigen (Figure 16B). This was confirmed against a purified cyst-specific 
recombinant protein, Gsc1 (Figure 16C). It is still unclear as to whether this decrease is due to 
antibody titer, affinity, or epitope differences, so we performed western with reduced and non-
reduced Pneumocystis antigen, and with serum from wild-type or IL21r-/- mice.  Mice deficient 
in IL21 signaling not only had weaker overall signal by western, but they also had different 
banding patterns (Figure 16D). These data suggests that IL21r-/- mice may have a defect in 
antigen recognition, presentation, and/or immunogenicity. We then tested the functionality of the 
serum antibodies in an in vitro killing assay of P. murina, and as expected, serum from IL21r-/- 
mice had impaired complement-mediated killing (Figure 16E). We next wanted to demonstrate 
this loss of functionality in an in vivo model, and as proof of concept, showed that adoptive 
transfer of ultra-convalescent serum (wild-type mice with multiple exposure to Pneumocystis) is 
enough to reduce burden by 2 to 3 logs (Figure 16F, left panel). Standard wild-type 
convalescent serum only reduced burden by half a log, however, IL21r-/- serum was not able to 
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significantly reduce burden in vivo (Figure 16F, right panel). Finally, we wanted to determine 
whether this immunodeficiency is associated with a defect in T follicular helper cell function, so 
we infected Cxcr5-/- mice with Pneumocystis. These mice, however, were fully capable of 
clearing infection, similar to the WT controls (Figure 16G).     
The ability for Cxcr5-/- mice to clear Pneumocystis suggests that the IL-21r-/- mice may 
also have additionally a T-cell defect, thus we examined whether intrinsic IL21 signaling on 
CD4+ T-cells is required for clearance. We adoptively transferred wild-type or receptor 
knockout CD4+ T-cells into Rag1-/- mice prior to infection (Figure 17A). Unlike the wild-type 
controls, IL21r-/- CD4+ T-cells provided no protection against Pneumocystis (Figure 17B). 
Although, IL21r-/- CD4+ T-cells were capable of infiltrating the lung (Figure 17C), there was a 
slight reduction in recruitment (Figure 17D, upper panel). Both wild-type and IL21r-/- CD4+ 
cells harvested from Rag1-/- mice were phenotypically similar, except, there was a small 
decrease in percentage of CD69+ CD127- CD4+ T-cells (Figure 17D, lower panel). Since 
activated IL21r-/- CD4+ T-cells are capable of being recruited to the lung, we next tried dissect 
differences in the effector signals produced by each. We observed no significant difference in 
most analytes including IFNγ, TNFα, IL-5, IL1β, and GM-CSF. Although, there was a slight 
reduction in IL-17, levels were still high compared to the no transfer controls (Figure 17E).  
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Figure 16. IL-21 signaling required for B-cell mediated clearance against P. murina infection 
(A) Total Chitin specific IgMs, (B) total P. murina antigen specific IgGs, and (C) total GSC-1 specific IgGs were 
measured by direct ELISA of a 1 to 64 dilution of serum as primary and anti-mouse IgG-HRP secondary. (D) 
Western blots of 10μg (non-reduced or reduced) Pneumocystis antigen were stained directly with 1:500 dilution of 
serum as primary and anti-mouse IgG HRP secondary. Images acquired by chemiluminescence. (E) In vitro killing 
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assay with non-heat-inactivated serum. Pneumocystis burden was measured by real-time PCR of the mitochondrial 
Small Subunit rRNA normalized to untreated control. (F) Rag1-/- mice treated with a single dose of serum prior to 4 
week infection. (G) Standard infection model. Pneumocystis burden was measured by real-time PCR of the 
mitochondrial Small Subunit rRNA copy number. Readouts are reported as means + SD for n ≥4 per group. P values 
are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny and T. 
Eddens. 
3.3.4 Defining a role for IL-22 during Pneumocystis infection. 
In order to identify the CD4 signals required for clearance, we differentiated naïve wild-type, 
Stat3-deficient, and IL21r-/- CD4+ T-cells in vitro under Th1, Th2 and Th17 conditions. We 
then analyzed the cytokine and chemokine profiles of each, and targeted factors that were 
impaired in both Stat3-deficient and IL21r-/- CD4+ T-cells. Stat3-deficient CD4+ T-cells had 
impaired production of many cytokines including IL-2, IL-13, IL-17A/F, IL-22, GM-CSF, 
CD40L, Mip3α, and TNFα/β. However, the IL-21r-/- CD4+ T-cells were only impaired in IL-22 
production (Figure 18A). To validate this in vivo, we transferred WT and IL-21r-/- CD4+ T-
cells into Rag1-/- mice, followed by P. murina infection for 2 weeks, and finally assayed purified 
CD4+ cells by RNAseq (Figure 18B). RNAseq analysis verified results from the T-cell 
differentiation assay, and revealed IL-22 expression during P. murina infection in wild-type 
mice, which was absent in IL-21r-/- mice (Figure 18C). 
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Figure 17. CD4 intrinsic IL21r signaling is required for protection 
(A) Diagram depicting standard adoptive transfer protocol. Briefly, splenic CD4+ cells are purified from control and 
experimental mice, then adoptively transferred intravenously signifying Day 0. Mice are rested as cells 
homeostatically proliferate for 2 weeks. Mice are then infected for 4 weeks prior to RNA, Protein, and cellular 
endpoint readouts. (B) Pneumocystis burden was measured by real-time PCR of the mitochondrial Small Subunit 
rRNA copy number. (C) Flow cytometry of whole lung from Rag1-/- mice without CD4 transfer (upper panel), with 
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WT CD4+ cell transfer (middle panel) and IL-21r-/- CD4+ cell transfer (lower panel). Panels are gated on 
lymphocyte FSC/SSC, and stained with Y-axis (CD3) and X-axis (CD4). Representative images of n ≥3 per group. 
(D) Cumulative percentage values from FACS panels (upper panel). (Lower panel) gated on CD3+CD4+, 
cumulative percentages of CD69+CD127- cells. (E) WLCs were cultured in the presence of P. murina antigen for 72 
hours. All cytokines were analyzed simultaneously by Millipore multiplex on a bioplex reader. All data are reported 
as means + SD for n ≥3 per group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) 
≤0.0001. Contributors: W. Elsegeiny and T. Eddens. 
To determine the physiological relevancy of IL-22 during Pneumocystis infection, we 
stained naïve and Pneumocystis infected lung tissue for IL-22 receptor (IL-22rα1). Naïve lungs 
do not stain for IL-22rα1 (Figure 18D), however, Pneumocystis infected lungs have intense 
staining throughout the alveolar space (Figure 18E). Upon closer inspection, the alveolar 
epithelial cells are surprisingly not the most intensely stained cell type, but instead large, 
globular, mononuclear cells (Figure 18E, red arrows). Interestingly, Rag1-/- mice infected with 
Pneumocystis lack these macrophage-like cells, which also revealed apparent staining of the 
trophic form of Pneumocystis (Figure 18F).   
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Figure 18. IL-22 signaling is increased during Pneumocystis infection 
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(A) Purified naïve CD4+ cells were cultured in Th17 conditions. IL-22 was one of a panel of cytokines that were 
analyzed simultaneously by multiplex analysis, n =2. (B) Diagram depicting in vivo T-cell phenotyping. Briefly, 
splenic CD4+ cells are purified, then adoptively transferred intravenously at Day 0. Mice are rested as cells 
homeostatically proliferate for 2 weeks. Mice are then infected for 2 weeks prior to retrieving CD4+ T-cells for 
RNA extraction and sequencing. (C) RNAseq intensity values for IL-22 gene expression in WT and IL21r-/- CD4+ 
T-cells, n ≥2. (D) Naïve WT, (E) 2 week P. murina infected WT, and (F) 4 week infected Rag1-/- representative 
images of mouse lung tissue, stained with anti-IL-22ra1 immunohistochemistry, n=3. All data are reported as means 
+ SD. Contributors: W. Elsegeiny, D. Pociask, Radha Gopal, and W. Horne. 
3.3.5 IL-22 supports the clearance of Pneumocystis 
To test whether IL-22 is required for clearance, we once again used the adoptive transfer model. 
Briefly, splenic CD4+ cells were purified from IL-22-/- mice and transferred into Rag1-/- mice. 
Mice were given two weeks for homeostatic proliferation and infected with P. murina for 4 
weeks (Figure 19A). At the end of week 4, IL-22-/- mice had significantly higher burden than 
wild-type controls (Figure 19B). Degree of clearance in wild-type CD4 recipients, was directly 
correlated with the expression of IL-22 and associated genes such as S100a8 (Figure 19C&D). 
However, during a 6 week infection, IL-22-/- CD4 recipients begin to clear infection, suggesting 
IL-22 may only play a supportive role (Figure 19E). It is also possible that there are multiple 
modes for clearance. Next we examined whether IL-22 was sufficient to mediate clearance. 
Briefly, IL-21r-/- mice were infected with P. murina for 2 weeks, followed by 4 doses of 
recombinant IL-22-FC over the following two weeks. Burden was examined at the end of the 4th 
week of infection (Figure 19F), and the IL21r-/- mice that received treatment had approximately 
a 10-fold reduction in burden (Figure 19G). Next we performed the same experiment with CD4-
depleted mice, however, IL-22 treatment had no effect (Figure 19H). 
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Figure 19. IL-22 supports clearance of P. murina infection 
(A) Diagram depicting standard adoptive transfer protocol. Briefly, splenic CD4+ cells are purified from control and 
experimental mice, then adoptively transferred intravenously signifying Day 0. Mice are rested as cells 
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homeostatically proliferate for 2 weeks. Mice are then infected for 4 weeks prior to endpoint readouts. (B) 
Pneumocystis burden was measured by real-time PCR of the mitochondrial Small Subunit rRNA copy number. 
(C.D) Gene expression was measured by real-time PCR, normalized to paired HPRT expression. (E) Diagram 
depicting IL22 treatment model. Briefly, IL21r-/- or CD4-depleted WT mice are infected with P. murina for 2 
weeks, followed by 2 weeks of IL-22-FC treatment at 2 doses per week. (F-G) Pneumocystis burden was measured 
by real-time PCR of the mitochondrial Small Subunit rRNA copy number. Burden and gene expression are reported 
as means + SD for n ≥3 per group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) 
≤0.0001. Contributors: W. Elsegeiny and L. Monin. 
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Figure 20. CD4+ T-cells produce GM-CSF during infection 
(A) Diagram depicting the CD4-phenotyping infection model with inoculation of P. murina defined as Day 0, 
followed by RNA and protein isolation at Day14. (B) An indirect GM-CSF ELISA using 25ul of whole lung protein 
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homogenate. n=5. (C) RNAseq intensity values for GM-CSF expression in WT control and CD4-depleted mice, n 
=3. (D) Diagram depicting standard adoptive transfer protocol. Briefly, splenic CD4+ cells are purified from control 
and experimental mice, then adoptively transferred intravenously signifying Day 0. Mice are rested as cells 
homeostatically proliferate for 2 weeks. Mice are then infected for 2 weeks prior to endpoint readouts. (E) Naïve 
CD4+ cells were stimulated under Th17 conditions. GM-CSF was one of a panel of cytokines that were analyzed 
simultaneously by Millipore multiplex on a bioplex reader, n =2. (C) RNAseq intensity values for GM-CSF 
expression in WT, DKO, and TKO adoptively transferred Rag1-/- lung RNA. Values are reported as means + SD. P 
values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. 
Elsegeiny, T. Eddens, and W. Horne. 
3.3.6 GM-CSF-producing CD4+ T-cells are required for clearance of P. murina infection.  
Since IL-22 alone was not sufficient to rescue CD4-depleted mice, we reexamined RNA and 
protein for factors expressed in IL-21r-/- mice that are absent in CD4-depleted mice. At 2 weeks 
of infection, wild-type mice have detectable levels of GM-CSF by ELISA and RNAseq, and this 
is diminished during CD4-depletion (Figure 20A-C). Similarly, Stat3-deficient CD4+ T-cells 
have ablated GM-CSF production during Th17 differentiation (Figure 20D&E). Also, upon 
adoptive transfer, Stat3-deficient CD4+ T-cells have diminished expression of Csf2 (Figure 
20D&F). 
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Figure 21. GM-CSF is required for P. murina clearance 
(A) Adoptive transfer model using WT or GM-CSF-/- CD4+ T-cells. Pneumocystis burden was measured by real-
time PCR of the mitochondrial Small Subunit rRNA copy number. (B) Gene expression was measured by real-time 
PCR, normalized to paired HPRT expression. (C) Total cells counts are estimated live cell numbers, calculated by 
Life technologies countess.  (D) Cumulative percentages of whole lung flow cytometry from Rag1-/- mice, and (E) 
calculated total numbers. Left panels is gated on CD3+CD4+ cells, middle panel is gated on F4/80+MHCII+, and 
right panel is gated on SiglecF+CD11b+. All readouts are reported as means + SD for n ≥4 per group. P values are 
annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. Contributors: W. Elsegeiny and T. 
Eddens; Z. Chroneos provides GM-CSF-/- splenocytes. 
 
Using the adoptive transfer model, we tested whether GM-CSF was required for P. 
murina clearance. GM-CSF-/- CD4+ T-cells did not provide protection when adoptively 
transferred into Rag1-/- mice (Figure 21A). Whole lung quantitative RNA analysis revealed that 
GM-CSF-/- CD4+ T-cell recipients had reduced arginase (Arg1) expression, but equivalent inos 
(Nos2). Also, unlike their wild-type controls, GM-CSF-/- CD4+ T-cell recipients have no 
upregulation of the C-type lectin receptor (CD209e), but have equivalent levels of mannose 
receptor C type 1 (Mrc1) (Figure 21B). GM-CSF-/- CD4+ T-cell recipients had equivalent 
counts of total cells (Figure 21C), CD4+ T-cells, and F4/80+ macrophages per lobe (Figure 
21D&E, left and middle panels). However, they did have significantly fewer recruited SiglecF+ 
eosinophils (Figure 21D&E, right panels). 
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Figure 22. GM-CSF and IL-22 work cooperatively to clear Pneumocystis infection 
(A) Diagram depicting GM-CSF +/- IL-22-FC treatment model. Briefly CD4-depleted WT mice are infected with P. 
murina for 2 weeks, followed by 2 weeks of recombinant GM-CSF treatment at 3 doses per week with or without 
IL-22-FC at 2 doses per week. (B) Pneumocystis burden was measured by real-time PCR of the mitochondrial Small 
Subunit rRNA copy number. (C,D) Pneumocystis cyst and troph specific gene expressions were measured by real-
time PCR, and normalized to paired HPRT expression. Burden and gene expressions are reported as means + SD for 
n =4 per group. P values are annotated as follows (*) ≤0.05, (**) ≤0.01, (***) ≤0.001, and (****) ≤0.0001. 
Contributors: W. Elsegeiny and T. Eddens. 
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Finally, we wanted to determine if GM-CSF and IL-22 functioned cooperatively to 
mediate clearance of Pneumocystis infection. CD4-depleted wild-type mice were infected with 
P. murina for 2 weeks then were given 6 doses of recombinant GM-CSF +/- 4 doses of IL-22-FC 
over the following 2 weeks (Figure 22A). Mice treated with GM-CSF alone showed no 
reduction in overall burden as measured by SSU, however, mice that received a combination of 
GM-CSF and IL-22 had a significant reduction in burden (Figure 22B). Interestingly, GM-CSF 
alone was capable reducing the trophic form of Pneumocystis (Figure 22C), however, only the 
combination of GM-CSF and IL-22 was able to reduce the cystic form (Figure 22D).     
3.4 DISCUSSION  
Since the implementation of combinational antiretroviral therapy and anti-fungal prophylaxis, 
Pneumocystis pneumonia has reemerged as a predominantly HIV-negative infection while still 
maintaining its rank as the leading opportunistic infection in HIV-positive patients. Although, 
much has been studied as to what factors may lead to susceptibility, CD4+ T-cell count below 
200 cells per microliter is still considered the primary indicator. However, the exact CD4+ T-cell 
effector functions that mediate clearance is still unknown. We initially attempted to address this 
question by infecting mice deficient in Th1, Th2, or Th17 immunity through the use of cytokine 
and cytokine receptor knockout mice. IL-12p40-/- mice have a defect in Th1 differentiation, thus 
are deficient in IFNγ production, while IL-4rα-/- mice are unable to signal through the Th2 
signature cytokine, IL-4. Finally, IL-23α-/- and IL-17rα-/- are incapable of mounting a Th17 
response. Surprisingly, none of these knockout mice were susceptible to Pneumocystis infection. 
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At this point, it could be speculated that more than one subset could mediate clearance, or that 
less conventional T helper signals are required.  
Thus, we took a broader approach and targeted the Stat transcription factors for each T 
helper subset. Stat4 and Stat6, which are involved in the differentiation of Th1 and Th2 cells, 
respectively, were not required for clearance of Pneumocystis infection. However, Stat3-
deficient T-cells, that are completely deficient in mounting Th17 responses, could not clear 
infection. This was also verified using adoptive transfer of Stat3-deficient CD4+ T-cells into 
Rag1-/- mice. Interestingly, Stat4/Stat6 double knockout CD4+ T-cells have enhanced Stat3 
function, which is correlated with improved clearance of Pneumocystis infection. Additionally 
removing Stat3 from Stat4/Stat6 DKO CD4+ T-cells leads to a loss of their protective capacity.  
Although Stat3 is required, RORc-/- CD4+ T-cells which are completely deficient in Th17 
responses, are capable of clearing infection. In short, a Th17-independent Stat3 response is 
required for CD4 mediated clearance of Pneumocystis. 
Stat3 plays a role in many cell types and is involved numerous functions from immunity 
to embryogenesis. In CD4+ T-cells, Stat3 can be activated by IL-6, but more recent literature 
suggests that IL-21 can activate Stat3 through a distinct route. In exploring the potential role of 
IL-21 signaling, we observed that IL-21 and IL-21 receptor knockout mice are susceptible to 
Pneumocystis infection. Patients with loss-of-function IL-21 receptor mutations suffer from a 
primary immunodeficiency syndrome, presenting with multiple infections including, 
Pneumocystis jirovecii [159].  IL-21r-/- mice have impaired antibody responses to Pneumocystis 
infection, particularly in the generation of effective IgG class-switched antibody responses. To 
rule out impaired T follicular helper functions as cause for this immunodeficiency, we 
demonstrated that Cxcr5-/- mice have no defect in clearance of Pneumocystis infection.  
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CD4+ T-cell responses, such as Tbx21 and Gata3, appeared to be intact in IL-21r-/- mice, 
though there was a slight decrease in RORc and RORα expression. Interestingly, adoptive 
transfer of IL-21r-/- CD4+ T-cells into Rag1-/- mice provided no protection against 
Pneumocystis infection, suggesting that IL21r-/- CD4+ T-cells have an impaired effector 
function. In order to define the missing signal, we performed RNA sequencing on CD4 cells 
purified from the Rag1-/- mice, and found a decrease of IL-22 in the IL-21r-/- mice. This was 
corroborated by the in ability of IL21r-/- CD4+ T-cells to produce IL-22 at the protein level, 
when differentiated under Th17 conditions. Additionally, it has been recently published that IL-
21 signaling is important for IL-22 production in a Ahr and Stat3 dependent pathway [160]. By 
staining, IL-22 receptor is upregulated during Pneumocystis infection, and appears to be 
primarily on macrophages. We explored the role of IL-22 production during P. murina infection 
by adoptively transferring IL-22-/- CD4+ T-cells into Rag1-/- mice and observed a decrease in 
efficiency of clearance. Furthermore, treatment of IL-21r-/- mice with IL-22 was able to 
significantly reduce burden. However, this effect could not be observed in CD4-depleted wild-
type mice, suggesting that IL-22 works in collaboration with at least one other factor to mediate 
clearance. GM-CSF has previously been shown to have some therapeutic effect during 
Pneumocystis infection [161], but even though IL-21r-/- mice express GM-CSF, they are not 
protected from infection.   
Considering GM-CSF as the potential co-signal for Pneumocystis clearance, we tested 
whether GM-CSF producing CD4+ T-cells were required for clearance. As expected, GM-CSF-
/- CD4+ T-cells could not provide protection in the adoptive transfer model. This was correlated 
with lower arginase and CD209e expression. Finally, when testing whether GM-CSF and IL-22 
 89 
could synergistically reduce burden in CD4-depleted WT mice, we observed a significant 
decrease in burden with the combinational treatment.  
To conclude, Stat3 signaling in CD4+ T-cells is required to generate a protective immune 
response against Pneumocystis infection, however, it is independent of IL-17 and IL-23 signals. 
We also identified IL-21 receptor as a key signaling pathway that is required to mediate 
clearance. Using a variety of approaches, we determined that GM-CSF and IL-22 play important 
roles during Pneumocystis infection. GM-CSF+ CD4+ T-cells are required for T-cell mediated 
clearance, however, it alone is not sufficient. While IL-22, although not required, is sufficient to 
reduce burden in IL-21 receptor knockout mice. These data suggest a model of clearance that 
requires non-classical T helper cell function may explain the discrepancies observed in previous 
studies. 
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4.0  CHAPTER 4: CONCLUSIONS AND FUTURE PERSPECTIVES 
Pneumocystis jirovecii pneumonia (PJP) has remained a major opportunistic infection in HIV-
positive patients, but in the last decade has reemerged as a primarily HIV-negative infection 
[162]. Patients that receive prophylaxis have lower risk of acquiring infection, and reduced 
disease severity and mortality. However, TMP-SMX, a relatively toxic drug, is the primary 
medication for prophylaxis, and is generally only prescribed to established at-risk populations. 
Identifying these at-risk populations can be complicated due to the combinational drug nature of 
patients that acquire infection. To determine if patients receiving anti-CD20 therapy are at risk 
for developing PJP, we developed an in vivo murine model of CD20-depletion. Our results 
confirmed that anti-CD20 alone is capable of inducing susceptibility to Pneumocystis infection 
by diminishing the immune response to Pneumocystis in the lung. We deduce that patients 
receiving anti-CD20 therapy should be considered as a risk group for Pneumocystis infection and 
be carefully monitored.  
However, it is important to consider that these experiments were conducted with naïve 
mice, and that most individuals are seropositive for anti-Pneumocystis antibodies [120, 146].  
Experimentally, we observed that convalescent mice are capable of clearing Pneumocystis 
without the aid of CD4 or CD20+ cells. Since memory CD4+ cells and antibodies are sufficient 
to clear Pneumocystis, these data raise a question as to why immunosuppressed patients acquire 
Pneumocystis jirovecii infections. Anti-CD20 antibody therapy in patients alone has not been 
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shown to decrease immunoglobulin levels, however, when combined with other  
immunosuppressive therapies hypogammaglobulinaemia can occur [148]. It has also been 
demonstrated that Pneumocystis can alter their major surface glycoproteins creating dynamic 
extracellular epitopes, which is implicated as a mechanism in evading the host immune response 
[149, 150]. Furthermore, reports of large genetic variability between Pneumocystis jirovecii 
isolates also suggests the possibility that patients are simply being exposed to a new strain or 
special form of Pneumocystis [143, 151]. 
We explored the underlying cause for susceptibility and found a general decrease in 
immune response, particularly type 2, in mice treated with anti-CD20. CD4+ T-cells specifically 
were not capable of providing protective responses in an adoptive transfer model, thus 
suggesting that anti-CD20 inhibits T-cell priming to P. murina. Interestingly, the absence of 
CD20+ B-cells during Pneumocystis infection may also lead to clonal deletion of Pneumocystis 
specific CD4+ cells. CD4+ T-cells from anti-CD20 treated mice are not as capable of clearing 
Pneumocystis as CD4+ T-cells cells from naïve mice. This may be due to a lack of CD4+ T-cell 
costimulation by B-cells during Pneumocystis infection, which would lead to cell death or 
anergy. It is still not understood why other antigen presenting cells (APCs) beside CD20+ B-
cells are not sufficient to compensate for the loss of CD20+ B-cells. CD40 and MHC class II on 
B-cells have been shown to be critical for the CD4+ T -cell priming, but these are not exclusively 
expressed on B cells. [89]. We hypothesize that a B-cell specific costimulatory molecule would 
be a plausible explanation for these results. 
To examine the role of Th2 responses during Pneumocystis infection, we first analyzed 
type 2 responses in an infection time-course model with WT and CD4-depleted mice. We found 
that IL-5 transcription levels peaked by day 7 post infection. This production was lost in CD4-
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depleted animals, suggesting an early adaptive immune response to infection. This led us to ask 
the question whether eosinophils play a role in Pneumocystis infection.  
Classically recognized as mediators of immunity against helminths, Eosinophils have 
recently been shown to play a role against a variety of pathogens, including bacterial, viral, and 
even fungal infections. For example, eosinophils contribute to host defense against Aspergillus 
fumigatus, a fungal pathogen, through a secretory factor. [144, 145]. In our studies, Gata1tm6Sho/J, 
eosinophil-deficient, mice had delayed clearance of P. murina infection, while mice treated with 
IL-5 had an eosinophilia-mediated reduction in burden. This was observed in both CD4-depleted 
and Rag1-/- mice, but not in the Gata1tm6Sho/J mice. In collaboration with Chad Steele, we also 
showed eosinophils display antifungal activity in vitro, and that addition of IL-4 and IL-13 
greatly enhanced killing of Pneumocystis. Cumulatively, these data suggest that Th2 cytokines in 
the lung may mediate some degree of clearance during Pneumocystis infection, and that anti-
CD20 therapy diminishes these responses.  
However, the CD4+ T-cell factors that are absolutely required for clearance are still 
unknown. Exploring the role of each T helper cell subset (Th1, Th2, or Th17), we used of variety 
of cytokine and cytokine receptor knockout mice. For example, we used IL-12p40-/- mice which 
have a defect in Th1 differentiation and IFNγ production, and IL-4rα-/- mice that are unable to 
signal through the Th2 signature cytokine, such as IL-4. To analyze the importance of Th17 
responses, we used IL-23α-/- and IL-17rα-/-. In short, none of these knockout mice are 
susceptible to Pneumocystis infection. This meant that either more than one subset could mediate 
clearance and compensate for the loss of another, or that less conventional T helper signals are 
required.  
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Taking a broader approach, we targeted the signal transducers and activators of 
transcription (Stat) for each T helper subset. Stat4, Stat6, and Stat3 are involved in the 
differentiation of Th1, Th2, and Th17 cells, respectively. Although, Stat4-/- and Stat6-/- mice 
could mediate clearance of Pneumocystis infection, T-cell specific Stat3-deficient mice are 
completely susceptible. This was confirmed by adoptively transferring of Stat3-deficient CD4+ 
T-cells into Rag1-/- mice. To determine whether Stat4 and Stat6 played supportive or 
compensatory roles, we generated Stat4/Stat6 double knockout (DKO) mice. Remarkably, DKO 
CD4+ T-cells have enhance clearance of Pneumocystis infection, which correlated with 
increased Stat3 function. Removing Stat3 from DKO CD4+ T-cells ablates their protective 
capacity, further clarifying the importance of Stat3.  Rorc-/- mice and CD4+ T-cells, although 
also lack most Th17 cell responses, do not have the same phenotype. This indicates that Stat3 
signaling in CD4+ T-cells is required for clearance of infection independent of Th17 responses.  
Stat3 is involved in many functions from embryogenesis to immunity. The specific cell 
types, signals, receptors, and cofactors that play a large role in mediating Stat3’s function are 
very numerous and complex. In the context of CD4+ T-cells, Stat3 is typically known to be 
activated by IL-6, but more recently literature suggests that IL-21 receptor on T-cells also signals 
through Stat3. T follicular helper cells are thought to be the primary producers of IL-21, thus we 
explored the role of T follicular helper cells and IL-21 during Pneumocystis infection. We 
observed that IL-21 and IL-21 receptor knockout mice were in fact susceptible to infection. This 
susceptibility translates clinically as patients with loss-of-function IL-21 receptor mutations 
present with a primary immunodeficiency syndrome complicated by multiple infections, 
including Pneumocystis jirovecii [159].  In our studies, IL-21r-/- mice have impaired antibody 
responses to Pneumocystis infection, specifically in the generation of class-switched antibody 
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responses, which can also be observed in patients with IL-21r mutations. This demonstrates that 
IL-21 is required for T helper cell function in B-cell activation. However, Cxcr5-/- mice, which 
are deficient in germinal centers, are capable of clearing Pneumocystis, suggesting that IL-21 
signaling must be required for more than just B-cell responses.  
Next we tested whether IL-21r-/- mice had defective CD4+ T-cell responses. 
Pneumocystis-infected lung tissue of IL21r-/- mice had normal expression of Tbx21 and Gata3, 
however, there was a modest decrease in RORc expression. We elucidated the CD4+ T-cell 
defect by adoptively transferring IL-21r-/- CD4+ T-cells to Rag1-/- mice. The IL-21r-/- CD4+ T-
cells were not able to provide any protection, although they were sufficiently recruited and 
activated in the lung. This suggested that IL21r-/- CD4+ T-cells have an impaired effector 
function, so we performed RNA sequencing on CD4+ cells purified from the Rag1-/- mice in 
order to define the missing signal. We found modest decrease of IL-22 in the IL-21r-/- CD4+ T-
cells, which was also reported in patients with loss of function IL-21 receptor mutation. 
Additionally, the direct connection between IL-21 receptor signaling on CD4+ T-cells and Stat3-
mediated production of IL-22 has recently been established by Yeste et al. 2014 [159, 160].  
To clarify the role for IL-22 during Pneumocystis infection, we stained for IL-22 receptor 
in lung tissue of Pneumocystis infected mice and observed a dramatic upregulation. IL-22 
receptor is believed to be expressed primarily on basolateral side of epithelial cells, and regulates 
production of antimicrobial peptides as well as apical surface carbohydrate composition.  
However, during Pneumocystis infection, most of the staining appears to be primarily on 
macrophages. To determine its importance, we adoptively transferring IL-22-/- CD4+ T-cells 
into Rag1-/- mice, but observed only a slight decrease in clearance efficiency. Interestingly, 
treatment of IL-21r-/- mice with IL-22 was able to reduce burden by up to 10 fold. However, this 
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effect could not be observed in CD4-depleted wild-type mice, suggesting that IL-22 works in 
collaboration with at least one other factor to mediate clearance. Using RNA and protein 
expression assays of Pneumocystis infected mice, we identified GM-CSF as a strong candidate. 
It has been shown that GM-CSF has some therapeutic effect during Pneumocystis infection 
[161], so we tested whether GM-CSF producing CD4+ T-cells were required for clearance. GM-
CSF-/- CD4+ T-cells could not provide protection in the adoptive transfer model, which was 
correlated with lower arginase and CD209e expression. However, treatment of CD4-depleted 
mice with GM-CSF alone did not aid in controlling infection. Finally, when testing whether GM-
CSF and IL-22 functioned cooperatively to reduce burden in CD4-depleted WT mice, we 
observed a significant decrease in burden. 
These studies have generated new insights to patient populations at risk for 
Pneumocystis, and several mechanisms that are involved in clearance. However, there are still 
many unanswered questions and anomalies that can be deduced from these studies. For example, 
different models of Pneumocystis infection present with different restriction. As mentioned 
above, anti-CD20 therapy in wild-type mice prevents the generation of primed CD4+ T-cell 
responses, however, naïve wild-type CD4 cells are capable of generating effector cytokines when 
adoptively transferred into Rag1-/- mice. Understanding the fundamental differences in antigen 
presentation and T-cell activation in these models could generate insights in ways to treat non-T 
cell associated immunodeficiency. Furthermore, we have shown that IL-5 has therapeutic effects 
in Rag1-/- mice, however, IL-21r-/- CD4+ T-cells, which produce wild-type levels of IL-5, do 
not provide protection; the same can be observed with GM-CSF. In addition, RORc-/- CD4+ T-
cell, which are deficient in IL-22 production, are capable of clearing Pneumocystis. This suggests 
that IL-21r-/- CD4+ T-cells may also produce factors that inhibit clearance. Identifying all the 
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factors involved in susceptibility and clearance would have clinical application and provide a 
deep understanding of the immune response. 
In summary of this and previous studies, infection is initially acquired by inhaling 
Pneumocystis ascospores or asci (Summary Figure A). As the pathogen propagates, innate 
immune machinery such as alveolar macrophages and dendritic cells acquire and respond to 
Pneumocystis antigens (Summary Figure B). Upon acquiring antigen, CD11c+ dendritic cells 
leave the lung and migrate to the draining lymph nodes (Summary Figure C). In the germinal 
centers, DCs present antigen within MHC class II molecules to CD4+ T-cells. In addition to 
antigen presentation, the CD4+ T-cells are also costimulated with CD40 and ICOS (Summary 
Figure D). Antigen presentation and costimulation by B-cells are also required to generate an 
effective CD4+ T-cells response, but it’s is unknown whether this is within the lung or lymph 
node, or what costimulatory molecules are required. Antigen-specific CD4+ T-cells migrate to 
the lung and early on, primed cells generate a Th2 response to infection. Production of IL-5, IL4, 
and IL-13 trigger Gata1-dependent eosinopoiesis, and stimulate eosinophil-mediated control of 
Pneumocystis infection (Summary Figure E). In addition, Stat3-activated CD4+ T-cells produce 
GM-CSF which is required for clearance. IL-21 signaling on CD4+ T-cells is also required for 
effector T-cell responses, which includes IL-22. Th1 and Th17 cytokines are also generated, but 
are not needed for clearance. We hypothesize that Stat3-mediated clearance functions by 
recruiting and activating macrophages, as well as altering epithelial interactions with the trophic 
forms of Pneumocystis (Summary Figure F). CD4+ T-cells, in an IL-21 dependent manner, will 
also generate a robust antibody response which is sufficient for protection against future 
infections (Summary Figure G).   
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Summary Figure. Immune Response to Pneumocystis Infection 
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APPENDIX A 
EOSINOPHILS CONTRIBUTE TO EARLY CLEARANCE OF PNEUMOCYSTIS 
MURINA INFECTION 
Work described in this section was partly published in the Journal of Immunology 
(J Immunol. 2015 Jul 1; 195(1) 185-93. doi: 10.4049/jimmunol.1403162.) by authors Taylor 
Eddens, Waleed Elsegeiny, Michael P. Nelson, William Horne, Brian T. Campfield, Chad Steele, 
and Jay K. Kolls 
© Copyright 2015. The American Association of Immunologists, Inc. 
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A.1 INTRODUCTION 
Pneumocystis jirovecii is a host-specific fungal pathogen that causes a diffuse interstitial 
pneumonia in immunocompromised individuals [41]. Pneumocystis remains the most common 
serious opportunistic infection in the HIV/AIDS population and is a frequent complication in 
developing countries where combination antiretroviral therapy (cART) and anti-Pneumocystis 
prophylaxis are difficult to implement [36, 37, 163-166]. In developed countries, the incidence of 
Pneumocystis infection has continued to rise due to the expansion of the immunosuppressed 
population [39, 40]. One study estimates that 75% of cases of Pneumocystis pneumonia are in 
non-HIV immunosuppressed individuals, such as those receiving immunosuppressive drug 
therapy for hematologic malignancy and post-transplantation rejection [39]. In fact, in the non-
HIV infected immunosuppressed population, Pneumocystis tends to have increased morbidity, 
such as higher rates of mechanical ventilation, and increased mortality compared to the HIV-
positive population [42, 43, 167]. 
 
Given the opportunistic nature of Pneumocystis, much can be gleaned about the host 
immune response required for clearance of Pneumocystis by examining the populations that are 
susceptible to infection. The HIV/AIDS population provides the strongest evidence; a clear 
inverse correlation exists between decreasing CD4+ T-cell counts and increasing susceptibility to 
Pneumocystis [34, 168-170]. The importance of CD4+ T-cells in protecting against Pneumocystis 
pneumonia has also been demonstrated in patients with a genetic immunodeficiency, such as 
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forms of severe combined immunodeficiency, as well as in animal models of infection [171, 
172]. Although CD4+ T-cells have been shown to interact with various cell types throughout the 
course of Pneumocystis infection, such as B cells and macrophages, the ability of other immune 
cell types to contribute to Pneumocystis clearance in a CD4+ T-cell dependent manner is still an 
area of active investigation [139, 141, 173-175]. Identifying novel cell types that mediate 
immunity to Pneumocystis could potentially suggest unique pathways for targeted therapeutic 
development.  
 
To investigate immunologic responses that may mediate clearance of Pneumocystis, we 
used RNA sequencing of whole lung at day 14 of Pneumocystis murina infection in CD4-
depleted (which develop chronic progressive infection) and wild type C57Bl/6 mice (which clear 
by 4 weeks). This analysis revealed a prominent eosinophil signature in wild type mice 
compared to CD4-depleted mice.  We also observed a substantial increase in recruited 
eosinophils in the bronchoalveolar lavage of infected CD4 replete mice compared to CD4 
depleted mice. Using hydrodynamic injection of a plasmid encoding IL-5, CD4-depleted and 
Rag1-/- knockout mice receiving pIL5 demonstrated significant eosinophilia in the lung and 
decreased Pneumocystis burden 14 days post-challenge. Finally, GATA1tm6Sho knockout mice 
deficient in eosinopoiesis had no difference in burden when treated with pIL5. Taken together, 
this study demonstrates that one role of CD4+ T-cells during Pneumocystis infection is to recruit 
eosinophils to the lung, which then contribute to clearance of Pneumocystis.  
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A.2 METHODS 
A.2.1 MICE 
C57Bl/6 mice, Rag1-/- knockout mice on a C57Bl/6 background, BALB/c mice, and 
Gata1tm6Sho/J mice were all ordered from The Jackson Laboratory [176]. Mice were all 6-8 week 
old females and were bred in the Rangos Research Building Animal Facility. All use of 
laboratory animals was approved and performed in accordance with the University of Pittsburgh 
Institutional Care and Use Committee. 
 
A.2.2 Pneumocystis infection time course and primary infections 
Twenty-five C57Bl/6 female mice were CD4-depleted using weekly intraperitoneal 
administration of 0.3 mg of GK1.5 monoclonal antibody per mouse and were subsequently 
challenged with 2.0 x 106/mL Pneumocystis murina cysts using oropharyngeal inoculation as 
previously described [139, 177, 178]. Twenty-five age-matched C57Bl/6 female mice were 
inoculated at the same time, but were not CD4-depleted. Five mice from each group were then 
sacrificed at day 0, 3, 7, 10, and 14. Four BALB/c and Gata1tm6Sho/J mice were also inoculated 
with Pneumocystis and sacrificed at day 14. Six uninfected BALB/c mice were used as naïve 
controls. 
 
 103 
A.2.3 RNA isolation and qRT-PCR  
Lung RNA was purified using Trizol® Reagent (Life Technologies). Briefly, lungs were 
homogenized and following the addition of chloroform, RNA in the aqueous phase was collected 
and precipitated in isopropanol. Following centrifugation, the RNA was washed with 75% 
ethanol, centrifuged again, and then resuspended in nuclease-free water. Following incubation at 
55°C, RNA was quantified using a Nanodrop and 1 μg of RNA was converted to cDNA using 
iScript™ cDNA synthesis kit per manufacturer’s instructions (Bio-Rad). PC burden was then 
quantified using SsoAdvanced qRT-PCR universal probes supermix (Bio-Rad) using primers and 
a probe specific for Pneumocystis murina small subunit (SSU) rRNA with a standard curve of 
known Pneumocystis SSU rRNA concentrations. SSU primer and probe sequences are as 
follows:  
Forward: 5’-CATTCCGAGAACGAACGCAATCCT;  
Reverse: 5’- TCGGACTTGGATCTTTGCTTCCCA;  
FAM-Probe: 5’- TCATGACCCTTATGGAGTGGGCTACA.   
Other primers used include: Prg2, Epx, Il5, Clca3, Muc5ac, Muc5b, and Il13 (Applied 
Biosystems). Prior to sequencing, the RNA was further purified using a Qiagen RNA cleanup kit 
with DNase treatment. 
 
A.2.4 RNA sequencing 
Total RNA from mouse whole lung was used to perform RNA sequencing. Each sample was 
assessed using Qubit 2.0 fluorimeter and Agilent Bioanalyzer Tape Station 2200 for RNA 
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quantity and quality. Library preparation was done using Illumina TruSeq Stranded mRNA 
sample prep kit. The first step in the workflow involves purifying the poly-A containing mRNA 
molecules using poly-T oligo attached magnetic beads. Following purification, the mRNA is 
fragmented into small pieces using divalent cations. The cleaved RNA fragments are copied into 
first strand cDNA using reverse transcriptase and random primers. Strand specificity is achieved 
by using dUTP in the Second Strand Marking Mix, followed by second strand cDNA synthesis 
using DNA polymerase I and RNase H. These cDNA fragments then have the addition of a 
single 'A' base and subsequent ligation of the adapter. The products are then purified and 
enriched with PCR to create the final cDNA library. The cDNA libraries are validated using 
KAPA Biosystems primer premix kit with Illumina-compatible DNA primers and Qubit 2.0 
fluorometer. Quality is examined using Agilent Bioanalyzer Tape station 2200.The cDNA 
libraries will be pooled at a final concentration 1.8pM. Cluster generation and 75bp paired read 
single-indexed sequencing was performed on Illumina NextSeq 500’s. 
 
A.2.5 RNA Seq Data Analysis  
Raw reads from an Illumina NextSeq 500 in fastq format were trimmed to remove 
adaptor/primer sequences. Trimmed reads were then aligned using BWA (version 0.5.9, settings 
aln -o 1 -e 10 -i 5 -k 2 -t 8) against the mouse genomic reference sequence. Additional alignment 
and post-processing were done with Picard tools (version 1.58) including local realignment and 
score recalibration (not duplicate marking) to generate a finale genomic aligned set of 
reads. Reads mapping to the genome were characterized as exon, intron, or intergenic (outside 
any annotated gene) using the matched annotation for the genomic reference sequence. The 
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remaining unmapped reads from the genomic alignment were then aligned to a splice reference 
created using all possible combinations of known exons (based on annotation described above) 
and then categorizing these as known or novel splice events. This aligned data is then used to 
calculate gene expression by taking the total of exon and known splice reads for each annotated 
gene to generate a count value per gene. For each gene there is also a normalized expression 
value generated in two ways: 1) Reads per Mapped Million (RPM), which is calculated by taking 
the count value and dividing it by the number of million mapped reads, 2) Reads per Mapped 
Million per Kilobase (RPKM), which is calculated by taking the RPM vale and dividing it by the 
kilobase length of the longest transcript for each gene. The RPM values are subsequently used 
for comparing gene expression across samples to remove the bias of different numbers of reads 
mapped per sample. RPKM values are subsequently used for comparing relative expression of 
genes to one another to remove the bias of different numbers of mapped reads and different 
transcript lengths. In addition to gene expression measurements, nucleotide variation was also 
detected using the GATK (version 1.3-25, -dcov 2000 -stand_call_conf 30.0 -stand_emit_conf 
10.0 -A DepthOfCoverage -A BaseCounts -A AlleleBalance), which identified single nucleotide 
and small insertion/deletion (indel) events using default settings. Mapped exonic reads per WT 
sample: 44,291,011; 23,432,350; 41,004,408; and 41,308,864. Mapped exonic reads per GK1.5 
sample: 23,305,058; 43,821,698; 122,834,770; and 29,805,804. Data were then filtered on a 
quality score of 20 and probed for eosinophil associated genes: Ear11, Ear5, Ccl8, Ccl24, Ccr3, 
Prg2, Ccl11, Ccl7, Il13, Ear10, Il5ra, Ear2, Csf2rb, Ccl5, Il5, Ear1, Il4 (did not pass quality 
filter), and Epx (did not pass quality filter). Data available at 
http://www.ncbi.nlm.nih.gov/bioproject/.  
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A.2.6 Bronchoalveolar lavage 
Wild type C57BL/6, and GK1.5 treated mice infected with Pneumocystis were anesthetized at 
day 14 post-infection and a 20g Exel Safelet Catheter (Exel International Co.) was inserted in the 
cricoid cartilage. The needle was then removed and 1 mL aliquots were inserted and removed 
from the lung using a 1 mL syringe (10 mL total). Bronchoalveolar lavage (BAL) cells were then 
spun at 300xg for 10 minutes, resuspended in PBS, and counted using Trypan Blue stain. 1x106 
cells were then transferred to a round bottom 96-well plate for staining and the remainder of cells 
was transferred to Trizol® Reagent for RNA isolation (as described above). Naïve (uninfected) 
mice were also examined as a control. 
 
A.2.7 IL-5 and Eotaxin-1 Luminex on lung homogenate 
Lung was collected in PBS containing protease inhibitors (Roche) and homogenized. We used a 
Bio-Plex Pro™ Assay (23-plex, Bio-Rad) according to the manufacturer’s recommendations.  
Briefly, the plate was treated with Bio-Plex assay buffer, followed by vortexing and two washes. 
Lung homogenates (undiluted), standards, and blanks were then added to the plate and incubated 
at room temperature for one hour shaking at 850 rpm, covered. Following three washes, 
detection antibodies were then diluted and added to each well. The plate was incubated as above. 
Following three washes, diluted SA-PE was added to each well and incubated at room 
temperature for 20 minutes on shaker. The plate was then washed three times and resuspended in 
assay buffer and beads were quantified using a Bio-Plex® MAGPIX™ (Bio-Rad). 
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A.2.8 Flow cytometry 
BAL cells or cells from digested lung (1x106 total) were spun at 300xg for 3 minutes, 
resuspended in PBS, and pelleted once more. Cells were then resuspended in PBS containing 2% 
heat-inactivated fetal bovine serum and 0.4 μg of anti-CD16/CD32 (eBioscience, clone: 93). 
Following a 15 minute incubation at 4°C, cells were stained with the following antibodies: 
SiglecF-PE (BD Pharmigen™, clone: E50-2440), CD11b-APC (BioLegend, clone: M1/70), 
GR1-PE-Cy7 (BD Pharmigen™, clone: RB6-8C5), CD11c-FITC (eBioscience, clone: N418), 
and F4/80-APC-e780 (eBioscience, clone: BM8). Following an hour incubation at 4°C, cells 
were washed with PBS, pelleted, and fixed (BD CytoFix™). Cells were then analyzed using a 
BD LSRII Flow Cytometer with compensation via OneComp eBeads (eBioscience).   
A.2.9 Eosinophil culture and Pneumocystis killing assay 
Bone marrow-derived eosinophils were generated using a previously described protocol [179] 
and per our previous work [145]. Briefly, bone marrow was isolated from naïve BALB/c mice 
and cells plated at 1 x 106
 
cells/ml in RPMI 1640 containing 20% FBS (Irvine Scientific, Santa 
Ana, CA), 2mM Glutamine, 25mM HEPES, 1X MEM nonessential amino acids, 1mM sodium 
pyruvate (all from Life Technologies BRL, Rockville, MD), 50μM β-mercaptoethanol (Sigma-
Aldrich, St. Louis, MO), 100 ng/ml stem cell factor and 100 ng/ml FLT3-L (both from 
Peprotech). After 4 days, cells were replated in the above media supplemented with 10 ng/ml IL-
5. After 10 days, bone marrow cells were fully differentiated into eosinophils. As previously 
reported [179], samples of 1x105
 
cells were taken for RNA analysis each time media was 
changed for real time PCR analysis of Epx for eosinophil development and Mpo (Applied 
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Biosystems) for neutrophil development. In addition, cells were cytospun onto glass slides, 
Giemsa stained and analyzed for morphology and purity by a murine pathologist in the 
Comparative Pathology Laboratory at the University of Alabama at Birmingham. On the tenth 
day, bone marrow-derived eosinophils were enumerated and utilized in experiments. Bone 
marrow-derived eosinophils (1 x 105) were then co-cultured with 1 x 103
 
Pneumocystis cysts in 
100μL for 18 h at 37°C and 5% CO2 alone or in the presence of 10 ng/mL of IL-4 and IL-13. 
Controls included P. murina cultured in the absence of eosinophils as well as in the presence or 
absence of IL-4 and IL-13. Total RNA was isolated from the contents of each well using 
TRIZOL LS reagent (Invitrogen, Carlsbad, CA) and Pneumocystis SSU burden was calculated as 
above. Percent killing was defined as previously described [141]. 
A.2.10 pIL5 and pCMV hydrodynamic injection 
An untagged, murine IL-5 expression vector (pIL5, Origene, MC208784) and an empty vector 
pCMV6 control (Origene, PS100001) were grown in Mix and go E. coli (Zymo Research) in 200 
mL of LB containing kanamycin and were prepared using an EndoFree Plasmid Maxi Kit 
(Qiagen) per manufacturer’s instructions. Following quantification of vector, 10 μg of vector was 
added to 2 mL of Ringer’s solution (0.9% NaCl, 0.03% KCL, and 0.016% CaCl2) and injected 
intravenously via the tail vein within 5 seconds, as previously described [103, 180].  
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A.2.11 IL-5 ELISA 
Serum IL-5 was quantified using BioLegend ELISA MAX™ Mouse IL-5 ELISA kit per 
manufacturer’s instructions. Briefly, a 96-well plate was coated with capture antibody and stored 
overnight at 4°C. Following washes with PBS + 0.05% Tween-20, the plate was blocked with 
assay diluent for 1 hour at room temperature. Serum samples (diluted 1:20) and IL-5 standard 
were diluted in assay diluent, added to the plate, and incubate overnight at 4°C. Detection 
antibody and diluted Avidin-HRP were then added to the plate, with washes in between 
additions, and the plate was developed with TMB substrate in the dark. Absorbance was then 
measured at 450 nm. 
A.2.12 Lung digestion 
The right superior lobe of lung was physically digested using scissors, followed by an hour and a 
half incubation in collagenase/DNase in a 37°C shaker at 250 rpm. Single cell suspensions were 
then strained using a 70μm filter, pelleted, and then resuspended in 10 mL PBS. Following 
enumeration using Trypan Blue, cells were stained for flow cytometry as described above. 
A.2.13 Histology 
The left main bronchus was clamped using forceps and 250μL of 10% formalin was injected into 
the bronchus. The lung tissue was then submerged in 10% formalin, paraffin-embedded, and 
processed by the Children’s Hospital of Pittsburgh Histology Core. Sections were then stained 
from H&E and PAS.  
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A.2.14 Statistics 
All statistics were performed using GraphPad Prism 6. Briefly, an unpaired, two-tailed student’s 
T test with a p<0.05 considered significant was used for all studies except for the BALB/c pIL-5 
treatment. Given the non-Gaussian distribution for the BALB/c pIL-5 treatment, a Mann-
Whitney nonparametric rank test was performed with a p<0.05 considered significant. For 
studies with three groups, a one-way ANOVA with Tukey’s multiple comparisons was used with 
a p<0.05 considered significant. A Kruskal-Wallis nonparametric test with Dunn’s multiple 
comparison’s test was used for gene expression analysis in the BALB/c primary challenge 
experiment with a p<0.05 considered significant. Linear regression was also performed using 
Prism and Pearson’s correlation coefficient calculations were performed. 
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A.3 RESULTS 
A.3.1 RNA sequencing of whole lung identifies an eosinophil signature early in 
Pneumocystis infection 
To further understand the role of CD4+ T-cells in Pneumocystis infection, we examined 
Pneumocystis burden in wild type and GK1.5 treated, CD4-depleted C57/Bl6 mice. In this study, 
at day 14 using quantitative real time PCR, wild type mice begin to clear infection as CD4-
depleted mice had a higher fungal burden at this time point (Figure 23A).  As an unbiased 
approach to investigate potential mechanisms of fungal clearance, we used RNA sequencing of 
whole lung at this time point to examine the signatures of potential effector cells. Strikingly, 
several genes associated with eosinophil function and recruitment, such as prg2 (major basic 
protein), il5ra (IL-5 receptor alpha), ccr3, ccl11 (eotaxin-1), ccl24 (eotaxin-2), were all 
significantly upregulated at day 14 of infection in wild type animals (Figures 23B,C). Another 
specific eosinophil marker, eosinophil-associated ribonuclease 2 (ear2), was also significantly 
upregulated in wild type animals, while less specific eosinophil-associated ribonucleases (ear5, 
ear10, ear11) also had higher expression in wild type animals. Importantly, in addition to a 
robust eosinophil signature at day 14 in wild type animals, IL-5 had significantly higher 
expression in wild type animals at the transcriptional level at day 7 and day 10 post-infection 
with Pneumocystis (Figure 23D). Importantly, prg2, an eosinophil associated gene, had a 10-
fold increase in expression at day 14 by qRT-PCR, similar to that detected by RNA sequencing 
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(Figure 23D). Furthermore, protein levels of IL-5 and eotaxin-1 (CCL11) were significantly 
higher in wild type animals at day 14 when compared to CD4-depleted mice (Figure 23E). 
 
Figure 23. RNA sequencing of whole lung shows a prominent CD4-dependent eosinophil signature at day 14 
of Pneumocystis infection 
A. Wild type or GK1.5 treated CD4-depleted C57Bl/6 mice were infected with 2.0 x 106 cysts/ml of Pneumocystis 
and were sacrificed at day 3, 7, 10, or 14 following infection (n=5 at each time point). Pneumocystis burden was 
calculated by qRT-PCR of the small subunit ribosomal RNA and a significant decrease was seen at day 14 (p<0.01 
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by student’s t-test). B. RNA sequencing of whole lung RNA at day 14 in GK1.5 treated and wild type mice shows 
increase in expression in genes associated with eosinophils (n=4 in each group). C. Histogram of expression values 
from heat map in B with * indicating p<0.05 by student’s t-test.  D. Il5 expression over the course of Pneumocystis 
infection normalized to Hprt and GK1.5 day 3 (fold change) shows increase of il5 at day 7 and 10 in wild type mice 
(* p<0.05, student’s t-test). Similar to the expression pattern seen by RNA sequencing, a ten-fold increase in Prg2 is 
seen at day 14 by qRT-PCR (p>0.05). E. IL-5 and Eotaxin-1 (CCL11) protein levels in lung homogenate at day 14 
as determined by Luminex (* p<0.05). Contributors: T. Eddens, W. Elsegeiny, and W. Horne. 
A.3.2 Eosinophils are present in bronchoalveolar lavage fluid early in infection 
To further clarify the CD4+ T-cell dependent eosinophil response to Pneumocystis infection, we 
sought to define the cell populations in the bronchoalveolar lavage (BAL) fluid of wild type and 
CD4-depleted animals at day 14. Cell populations in naïve mice were also analyzed. A 
population of cells with high side scatter was present in animals with intact CD4+ T-cell 
responses, but absent in naïve and CD4-depleted animals infected with Pneumocystis (Figure 
24A, left panel). After gating on all cells, a population of SiglecF+CD11b+ cells was noted in the 
wild type animals, but this population was substantially reduced back to naïve levels in animals 
treated with GK1.5 (Figure 24A, right panel). The SiglecF+CD11b+ population represented over 
60% of cells in BAL fluid in wild type mice, while less than 2% of cells were SiglecF+CD11b+ in 
mice treated with GK1.5 (Figure 24B). Additionally, the RNA from BAL cell pellets was 
enriched for transcripts associated with eosinophils; Epx and Prg2 expression was nearly 1000-
fold higher in BAL cell pellets from wild type mice when compared to naïve and CD4-depleted 
mice (Figure 24C).  
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Figure 24. CD4-dependent recruitment of eosinophils to the lung at day 14 of Pneumocystis infection 
A. Bronchoalveolar lavage (BAL) of naïve (uninfected), wild type, and GK1.5 treated CD4-depleted mice 14 days 
post-inoculation with Pneumocystis shows a large population of cells with high side-scatter in wild type mice (left 
panel). The cells were gated as shown (left panel), and a SiglecF+CD11b+ population was seen in the wild type, but 
not the naïve or GK1.5 treated animals (right panel). B. Significant increase in percentage of SiglecF+CD11b+ cells 
in wild type animals compared to naïve and GK1.5 treated animals (n=4-5, **** p<0.0001 by one-way ANOVA 
with Tukey’s multiple comparisons). C. qRT-PCR for Epx (top) and Prg2 (bottom) on RNA extracted from BAL 
cell pellets shows significant increase in expression in wild type animals compared to naïve and GK1.5 treated 
animals (* p<0.05 by one-way ANOVA with Tukey’s multiple comparisons). Contributors: W. Elsegeiny and T. 
Eddens. 
A.3.3 Eosinophils contribute to control of Pneumocystis infection both in vitro and in vivo 
To determine the role of eosinophils in Pneumocystis infection, we used a loss-of-function 
approach and infected eosinopoiesis-deficient Gata1tm6Sho/J mice and BALB/c controls. 
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Gata1tm6Sho/J mice had an increased Pneumocystis burden at day 14 post infection compared to 
control BALB/c mice, while uninfected BALB/c had no detectable Pneumocystis burden (Figure 
25A). BALB/c mice had an increase in Epx expression and a modest increase in Prg2 expression 
compared to Gata1tm6Sho/J mice and BALB/c uninfected controls (Figure 25B). Eosinophils 
cultured from BALB/c bone marrow also demonstrated anti-Pneumocystis activity in vitro 
(Figure 25C). Furthermore, bone marrow derived eosinophils displayed increased Pneumocystis 
killing activity when co-cultured with IL-4 and IL-13 (Figure 25D). 
 
Figure 25. Eosinophils contribute to control of Pneumocystis infection both in vitro and in vivo 
A. BALB/c and Gata1tm6Sho/J knockout mice were infected with Pneumocystis and sacrificed at day 14 post-
infection and SSU burden was quantified by qRT-PCR (** p<0.01 by student’s T test). Uninfected BALB/c mice 
have no detectable Pneumocystis burden. B. qRT-PCR for Epx (left) and Prg2 (right) on RNA from whole lung 
shows significant increase in BALB/c mice infected with Pneumocystis compared to uninfected BALB/c and 
infected Gata1tm6Sho/J knockout mice (* p<0.05 by Kruskal-Wallis test w/ Dunn’s multiple comparisons test). C. 
Bone marrow derived eosinophils from BALB/c mice demonstrate anti-Pneumocystis activity when co-cultured in 
vitro for 24 hours at an eosinophil to P. murina cyst ratio of 100:1 (*** p<0.0001, student’s t-test). D. BM-derived 
eosinophils show enhanced killing activity when co-cultured with Pneumocystis in the presence of 10 ng/ml of IL-4 
and IL-13 compared to P. murina alone (** p<0.01 by student’s T-test). Contributors: T. Eddens and M. Nelson. 
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A.3.4 Hydrodynamic injection of IL-5 promotes Pneumocystis clearance in CD4-depleted 
C57Bl/6 and Rag1-/- mice 
To induce eosinophilia prior to Pneumocystis infection, we employed hydrodynamic injection 
with either a plasmid expressing IL-5 (pIL5) or an empty plasmid control (pCMV) in C57Bl/6 
mice treated with GK1.5 or Rag1-/- mice three days prior to infection (Figure 26A). At day two 
following infection, mice treated with pIL5 had over a log-fold increase in serum IL-5 (Figure 
26B). At day 14 of infection, treatment with pIL5 resulted in an increased abundance of a high 
side scatter population and a SiglecF+CD11b+ population in both CD4-depleted C57Bl/6 and 
Rag1-/- mice (Figure 26C). While these populations were present by flow cytometry in the 
groups treated with pCMV alone (Figure 26C, left panel), C57Bl/6 and Rag1-/- mice treated 
with pIL5 had significantly more SiglecF+CD11b+ cells as measured by both percentage and total 
cell number recovered from the lung (Figure 26D).  
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Figure 26. Treatment of CD4-depleted C57Bl/6 and Rag1-/- mice with pIL5 results in eosinophilia in 
whole lung and decreased Pneumocystis burden 
A. Schematic showing timing of hydrodynamic injection of either pCMV or pIL5 (day -3 and 4) and Pneumocystis 
inoculation (day 0) into GK1.5 treated C57Bl/6 (B6) or Rag1-/- mice. B. Serum IL-5 ELISA at day 2 post infection 
shows log-fold increase in IL-5 in pIL5 treated animals (n=4-7, dotted line represents limit of detection). C. 
Digested whole lung shows a high side scatter population in the pIL5 groups compared to the pCMV treated groups 
(left panel). The cells were gated as shown (left panel), and a SiglecF+CD11b+ population was seen in both the B6 
and Rag1-/- mice treated with pIL5 at day 14 post infection (right panel). D. pIL5 treatment resulted in a statistically 
significant increase in percentage (top) and total number (bottom) of SiglecF+CD11b+ cells (* p<0.05, ** p<0.01 by 
student’s t-test). E. pIL5 treatment results in statistically significant reduction in Pneumocystis burden as measured 
by qRT-PCR of small subunit ribosomal RNA at day 14 post infection (* p<0.05, *** p<0.001 by student’s t-test). 
F. H&E staining on paraffin-embedded lung sections demonstrating eosinophils (black arrowheads) in both the B6 
and Rag1-/- mice treated with pIL5 at 60X magnification. G. qRT-PCR for Epx (left) and Prg2 (right) on RNA 
extracted from whole lung shows significant log-fold increase in expression in pIL5 treated animals compared to 
pCMV treated mice (* p<0.05 by student’s T test). Contributors: T. Eddens and W. Elsegeiny. 
 
Strikingly, both the CD4-depleted C57Bl/6 and Rag1-/- mice receiving pIL5 had a 
statistically significant reduction in Pneumocystis burden by day 14 of infection when compared 
to mice treated with pCMV (Figure 26E). While the average difference in burden was 
approximately a half-log in both cohorts, some individual mice had greater than a log-reduction 
in Pneumocystis burden with pIL5 treatment. A strong negative correlation existed between total 
number of eosinophils recruited to the lung and Pneumocystis burden in the C57Bl/6 treated 
animals (Figure 27, p=0.0003).  Recruitment of eosinophils to the lung could also be observed 
by H&E staining in mice receiving pIL5 (Figure 26F). The pIL5 treated mice also had a ten-fold 
increase in expression of Epx and Prg2 in whole lung RNA when compared to pCMV treated 
mice (Figure 26G). Furthermore, although pIL5 treatment increased eosinophilic lung 
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inflammation, this was not associated with Type 2 immune inflammation as measured by goblet 
cell hyperplasia or mucin expression (as measured by qRT-PCR of Clca3, Muc5ac and PAS 
staining) or Il13 expression in the pIL5 treated C57Bl/6 mice.  
 
 
 
A.3.5 IL-5 mediated decrease in Pneumocystis burden is abrogated in eosinophil-deficient 
Gata1tm6Sho/J mice 
To verify the effect of pIL5 required eosinopoiesis, we used a genetic approach. CD4-depleted 
BALB/c mice were treated with pIL5 as described above and similar levels of IL-5 were induced 
in the serum (Figure 28A). Similarly, increased eosinophils were noted in the lung digest of 
pIL5 treated BALB/c mice (Figure 28B). pIL5 treated BALB/c mice had a statistically 
Figure 27. Eosinophil numbers correlates with Pneumocystis killing in vivo 
Correlation between the log of total SiglecF+ CD11b+ cells with the log of Pneumocystis 
SSU burden demonstrates a strong negative correlation in B6 mice. Solid line represents 
linear regression of data points and dashed lines represent 95% confidence interval (r=-
0.9485, p=0.0003 by Pearson’s correlation). Contributors: T. Eddens 
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significant increase in total number and a trend towards higher percentage of SiglecF+/CD11b+ 
cells compared to pCMV treated BALB/c mice (Figure 28C). Furthermore, upon sacrifice, 
BALB/c mice treated with pIL5 had nearly a 50% reduction in Pneumocystis burden when 
compared to pCMV treated animals (Figure 28D, p=0.04). Burden in this case was normalized 
to the pCMV group as the inoculums over three independent experiments varied; however, a 
similar reduction in burden was noted with C57Bl/6 and Rag1-/- mice (Figure 28E). Also 
noteworthy, four pIL5 treated mice had no induction of serum IL-5 and lacked eosinophils in the 
lung at day 14 by flow cytometry, likely due to technical variation. If only mice that responded 
to pIL5 treatment were included in the analysis, the mean percentage of Pneumocystis remaining 
in pIL5 treated mice would be 26% compared to 100% of pCMV treated mice (p<0.0002). The 
increased Pneumocystis killing in mice that recruited eosinophils to the lungs is also evident in 
the strong negative correlation that exists between Pneumocystis burden and total 
SiglecF+CD11b+ recruited cells. Hydrodynamic IL5 treatment was also associated with 
significant increases in eosinophil associated genes such as Epx and Prg2 (Figure 28E).  
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Figure 28. pIL5 treatment can reduce Pneumocystis burden in CD4-depleted BALB/c mice 
A. Serum IL-5 ELISA at day 2 post infection shows over a log-fold increase in IL-5 in pIL5 treated BALB/c mice 
(n=10-13, dotted line represents limit of detection). B. Digested whole lung shows a high side scatter population in 
the pIL5 groups compared to the pCMV treated groups (left panel). The cells were gated as shown (left panel), and a 
SiglecF+CD11b+ population was seen in the BALB/c mice treated with pIL5 (right panel). C. pIL5 treatment 
resulted in an increase in percentage (top) and total number (bottom) of SiglecF+CD11b+ cells (* p<0.05, Mann 
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Whitney test). D. pIL5 treatment results in reduction in Pneumocystis burden as measured by qRT-PCR of small 
subunit ribosomal RNA at day 14 post infection (* p=0.0481 by student’s t-test). E. qRT-PCR for Epx (left) and 
Prg2 (right) on RNA extracted from whole lung shows significant log-fold increase in expression in pIL5 treated 
animals compared to pCMV treated mice (** p<0.01 by Mann Whitney test). Contributors: T. Eddens and W. 
Elsegeiny, and B. Campfield.  
In contrast, Gata1tm6Sho/J mice (on a BALB/c background), mice that are deficient in 
eosinopoiesis, that were CD4-depleted and treated with pIL5 or pCMV as described above failed 
to show an effect of pIL5 on fungal burden, despite similar levels of IL-5 compared to previous 
mouse strains (Figure 29A,B). Consistent with no reduction in fungal burden, there was no 
observable eosinophil recruitment was detected in the lungs of Gata1tm6Sho/J mice, as neither a 
high side-scatter population nor a SiglecF+CD11b+ was noted by flow cytometry (Figure 
29C,D). Furthermore, there was no induction of Epx or Prg2 in the Gata1tm6Sho/J mice treated 
with pIL5 (Figure 29E). 
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Figure 29. pIL5 treatment cannot rescue eosinophil-deficient Gata1tm6Sho/J knockout mice 
A. Serum IL-5 ELISA at day 2 post infection shows nearly a log increase in Gata1tm6Sho/J pIL5 treated animals 
(n=4, dotted line represents limit of detection). B. pIL5 treatment does not reduce Pneumocystis burden at day 14 
post infection in Gata1tm6Sho/J mice as measured by qRT-PCR of small subunit ribosomal RNA. C. Digested 
whole lung shows no difference in high side scatter populations (left panel) or SiglecF+CD11b+ cells (right panel) 
independent of pIL5 treatment status. D. pIL5 treated Gata1tm6Sho/J mice showed no difference in percentage (top) 
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or total number (bottom) of SiglecF+CD11b+ cells. E. qRT-PCR for Epx (left) and Prg2 (right) on RNA extracted 
from whole lung shows no increase in eosinophil associated genes in Gata1tm6Sho/J mice. Contributors: T. Eddens.  
A.4 DISCUSSION 
The current study utilized an unbiased RNA sequencing based approach towards evaluating the 
role of CD4+ T-cells in Pneumocystis infection and suggested that CD4+ T-cells can recruit 
eosinophils to the lung by day 14 of infection by RNA sequencing. Eosinophils were also shown 
to have a role in immunity against Pneumocystis in a primary challenge model of eosinophil-
deficient mice and in an eosinophil-based Pneumocystis in vitro killing assay. Furthermore, 
induction of eosinophilia via hydrodynamic injection of pIL5 was capable of reducing 
Pneumocystis burden in vivo in both CD4-depleted C57Bl/6 and Rag1-/- mice. Finally, the same 
technique was able to reduce Pneumocystis burden in CD4-depleted BALB/c mice but failed to 
provide any therapeutic benefit in CD4-depleted Gata1tm6Sho/J mice, further implicating 
eosinophils as a novel cell population responsible for in vivo antifungal activity.  
CD4+ T-cells have been established as crucial mediators to Pneumocystis due to the high 
incidence of Pneumocystis in HIV/AIDS patients with low CD4+ T-cell counts [41, 164]. One 
clear role of CD4+ T-cells in response to Pneumocystis is to stimulate antibody responses by 
providing co-stimulatory signals to B cells [173, 175]. Antibodies against Pneumocystis are 
protective; however, at day 14 of infection, prior to antibody production, Pneumocystis burden 
has already plateaued in wild type animals suggesting an antibody-independent function for CD4 
cells [175]. As such, CD4+ T-cells appear to recruit eosinophils early in infection while B cells 
are undergoing maturation into antibody-producing plasma cells and provide preliminary control 
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of Pneumocystis burden. Importantly, IL-5 transcription and eosinophil recruitment appears to be 
dependent on CD4+ T-cells in this model, as such markers do not appear until after activation of 
the adaptive immune response at day 7 post-infection.  
Eosinophils, classically recognized as mediators of immunity against helminths, have 
recently been implicated in host defense against a variety of pathogens, including bacterial and 
viral infections [144]. Recently, we have demonstrated that eosinophils contribute to host 
defense against the fungal pathogen Aspergillus fumigates through a secretory factor, as 
eosinophils could mediate fungal killing when separated using transwells [145]. The current 
study extends these findings by demonstrating that eosinophil-deficient mice are more 
susceptible to Pneumocystis infection and that eosinophils display antifungal activity in vitro. 
Additionally, treatment of bone marrow derived eosinophils with IL-4 and IL-13 greatly 
enhanced killing of Pneumocystis, suggesting that Th2 cytokines in the lung may augment 
eosinophil-dependent antifungal activity.  
There are also several lines of evidence that connect Pneumocystis related pathology and 
eosinophils in both human disease and mouse models. First, eosinophilia in the bronchoalveolar 
lavage fluid of HIV-positive patients with Pneumocystis pneumonia has been well documented; 
however, whether a correlation exists between high eosinophil counts and lower Pneumocystis 
burden in these patients is unknown [181, 182]. Secondly, patients with a history of 
Pneumocystis or bacterial pneumonia had a significantly higher rate of physician-diagnosed 
asthma, a disease that has a well-established eosinophilic component in regards to pathogenesis 
[183]. Murine models of Pneumocystis have also shown Stat6, a transcription factor required for 
Th2 responses, is necessary for the development of airway hyperresponsiveness early in the 
course of infection [175]. While eosinophilia was also documented early in this murine model, 
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the study further links a Th2 response, and potentially eosinophilia, with pathology in the context 
of Pneumocystis infection [175]. Additionally studies have shown that CD8+ T-cells may 
moderate the interactions between CD4+ T-cells and eosinophils, although all three cell types 
may contribute to Pneumocystis driven pulmonary pathology [156]. 
However, the current study suggests that eosinophils are more than just the byproduct of 
a misguided immune response that drives airway hyperresponsiveness and pathology. The 
current study demonstrates that eosinophils have antifungal effects against Pneumocystis 
infection in vitro and in vivo and appear to be recruited to the lung by CD4+ T-cells early in 
infection. Additionally, the role of eosinophils as a potential therapeutic in the setting of 
HIV/AIDS may warrant further exploration, as IL-5 mediated eosinophilia can provide reduced 
Pneumocystis burden even in the setting of complete loss of T cells and B cells. Furthermore, 
such robust eosinophilia actually appeared to mitigate airway pathology (e.g. mucus production) 
suggesting that Pneumocystis burden may play an equally important role in driving airway 
hyperresponsiveness.  These findings provide evidence that the specific pathways responsible for 
protective and pathologic effects in Pneumocystis pneumonia may be independent and may allow 
for the targeted use of eosinophil-based treatments for Pneumocystis while avoiding concurrent 
pathology. 
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